Biological significance of MYC and CEBPD coamplification in urothelial carcinoma: Multilayered genomic, transcriptional and posttranscriptional positive feedback loops enhance oncogenic glycolysis

Ti-Chun Chan¹,² | Yi-Ting Chen³ | Kien Thiam Tan⁴ | Chia-Ling Wu⁴ | Wen-Jeng Wu⁵,⁶,⁷,⁸ | Wei-Ming Li⁵,⁶,⁷,⁸ | Ju-Ming Wang³ | Yow-Ling Shiue⁹,¹⁰ | Chien-Feng Li¹,²,⁹,¹⁰

¹ Department of Medical Research, Chi Mei Medical Center, Tainan, Taiwan
² National Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan
³ Department of Biotechnology and Bioindustry Sciences, College of Bioscience and Biotechnology, National Cheng Kung University, Tainan, Taiwan
⁴ ACT Genomics Co., Ltd., Taipei, Taiwan
⁵ Graduate Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan
⁶ Department of Urology, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan
⁷ Department of Urology, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan
⁸ Department of Urology, Ministry of Health and Welfare Pingtung Hospital, Pingtung, Taiwan
⁹ Institute of Precision Medicine, National Sun Yat-Sen University, Kaohsiung, Taiwan
¹⁰ Department of Pathology, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan

Graphical Abstract

• MYC and CEBPD coamplification predicts poor outcomes in urothelial carcinoma.
• MYC enhances amplification-driven CEBPD expression and CEBPD stabilize MYC protein through transcriptional suppression of FBXW7, forming a positive feedback loop.
• CEBPD facilitates the switch from mitochondrial oxidative phosphorylation to glycolysis in both MYC-dependent and a Myc-independent CEBPD - hsa-miR-429 - HK2 regulatory axis that confers pro-proliferative effect aggravated by high glucose condition.
Biological significance of MYC and CEBPD coamplification in urothelial carcinoma: Multilayered genomic, transcriptional and posttranscriptional positive feedback loops enhance oncogenic glycolysis

Ti-Chun Chan¹,² | Yi-Ting Chen³ | Kien Thiam Tan⁴ | Chia-Ling Wu⁴ | Wen-Jeng Wu⁵,⁶,⁷,⁸ | Wei-Ming Li⁵,⁶,⁷,⁸ | Ju-Ming Wang³ | Yow-Ling Shiue⁹,¹⁰ | Chien-Feng Li¹,²,⁹,¹⁰

¹ Department of Medical Research, Chi Mei Medical Center, Tainan, Taiwan
² National Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan
³ Department of Biotechnology and Bioindustry Sciences, College of Bioscience and Biotechnology, National Cheng Kung University, Tainan, Taiwan
⁴ ACT Genomics Co., Ltd., Taipei, Taiwan
⁵ Graduate Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan
⁶ Department of Urology, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan
⁷ Department of Urology, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan
⁸ Department of Urology, Ministry of Health and Welfare Pingtung Hospital, Pingtung, Taiwan
⁹ Institute of Precision Medicine, National Sun Yat-Sen University, Kaohsiung, Taiwan
¹⁰ Department of Pathology, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan

Correspondence
Chien-Feng Li, Department of Medical Research, Chi Mei Medical Center, 901 Chunghwa Road, Yung Kang District, Tainan City 710, Taiwan.
Email: angelo.p@yahoo.com.tw

Funding information
Academia Sinica Core Facility and Innovative Instrument Project, Grant/Award Number: AS-CFII-108-114; Ministry of Science and Technology of Taiwan, Grant/Award Numbers: 109-2628-B-384-003, 109-2628-B-037-110-MY3, 110-2628-B-384-001; National Health Research Institutes of Taiwan, Grant/Award Number: CA-I10-PP-11

Abstract

Background and purpose: The aim of this study is to decipher the underlying mechanisms of CCAAT/enhancer-binding protein delta (CEBPD)-enhanced glycolysis as well as the biological significance of CEBPD and MYC coamplification in urothelial carcinoma (UC).

Methods: In vitro analyses were conducted to examine the effects of altered CEBPD or MYC expression on UC cells. The in vivo effects of CEBPD overexpression in a high-glucose environment on tumour growth were investigated in xenografted induced diabetic severe combined immunodeficiency/beige mice. Data mining was used to cross-validate the associations between CEBPD and MYC copy number and transcriptional expression, quantitative reverse transcription-polymerase chain reaction, immunohistochemistry, chromogenic in situ hybridization, and in situ hybridization targeting microRNA were performed on 635 UC patient samples and xenograft samples. UC patient survival...
in relation to diabetes was validated by using the National Health Insurance Research Database.

**Results:** CEBPD and MYC coamplification (29.6%) occurred at a high frequency. MYC expression promoted chromosomal instability, facilitating CEBPD copy number gain and expression. CEBPD promoted glucose uptake and lactate production by upregulating SLC2A1 and HK2, leading to mitochondrial fission, increased extracellular acidification rate and decreased oxygen consumption rate to fuel cell growth. CEBPD upregulated HK2 expression through multiple regulation pathways including MYC stabilization, suppression of FBXW7 transactivation and MYC-independent transcriptional suppression of hsa-miR-429. Clinical and xenografted experiments confirmed the growth advantage of CEBPD in relation to glucose metabolic dysregulation and the significant correlations between the expression of these genes.

**Conclusions:** We confirmed that CEBPD has an oncogenic role in UC by activating AKT signalling and initiating metabolic reprogramming from mitochondrial oxidative phosphorylation to glycolysis to satisfy glucose addiction. These novel CEBPD- and MYC-centric multilayered positive feedback loops enhance cancer growth that could complement theranostic approaches.

**Keywords**
CEBPD, coamplification, glycolysis, MYC, urothelial carcinoma

---

**INTRODUCTION**

Urothelial carcinoma (UC), also known as transitional cell carcinoma, is a highly prevalent malignancy worldwide. Urinary bladder UC (UBUC) accounts for the majority (90%–95%) of UCs, while the remaining 5%–10% of UCs are upper urinary tract urothelial cancer (UTUC). UTUC exhibits an unusual prevalence in some countries, such as Taiwan. Combining standard treatment with molecularly matched targeted therapy based on biomarkers is emerging as a viable strategy to improve cancer management. However, the high genetic and histological heterogeneity of UC presents a challenge in terms of its diagnosis, conventional therapy response, and prognostication.

Environmental toxins, infections and genetic aberrations impact the progression of UC. Genomic instability (CIN) is a cancer hallmark featured by an increased tendency of genome alteration during cell division owing to the defects in DNA damage checkpoint, DNA repair machinery as well as a mitotic checkpoint. Of these, CIN is suggested as a consequence of MYC-induced DNA replication aberration and cell division dysregulation. Numerical CIN, which is related to the gain/loss of whole chromosomes, or structural CIN, which is involved in the amplification/deletion/inversion/translocation of chromosomal regions, have been shown to have a profound impact on the carcinogenesis of UC and have become prospective therapeutic targets.

Recently, we showed that the CIN involving 8q11.21 is linked to poor outcomes in our array comparative genomic hybridization (aCGH) UBUC cohort (n = 40). Within that CIN region, amplification of CCAAT/enhancer-binding protein delta (CEBPD) was linked to an adverse prognosis due to rapid tumour proliferation and metastasis. CEBPD encodes a transcription factor responsible for physiological processes, including cell differentiation, proliferation, metabolism, inflammation, growth arrest, and cell death. Of note, CEBPD has dual functions as a tumour suppressor in breast cancer and pancreas cancer but an oncogene in glioblastoma and UC depending on the environmental stimulus and cancer type. Surprisingly, in the present study, we reanalysed our previously published UBUC aCGH dataset and TCGA dataset with special attention to the chromosome 8q which is the most frequently gained region. CEBPD amplification is frequently accompanied by MYC protooncogene (MYC) amplification (both p < .01). Oncogenic MYC is located on chromosome 8q24.21, which is 80 Mb away from CEBPD, and contributes to tumour progression via metabolic reprogramming (i.e., aerobic glycolysis). Dysregulation of MYC has also been shown to be involved in genome instability, where MYC amplification has been reported to be closely
linked to ERBB2 proto-oncogene (mapped to 17q12) amplification to strongly activate cell proliferation in breast cancer. In addition, MYC overexpression drives dihydrofolate reductase (DHFR, mapped to 5q14.1) amplification, which increases metastatic risk. Because MYC amplification occurs earlier and more frequently than CEBPD amplification in our cohort, we hypothesized that CEBPD amplification might be closely associated with and at least partly driven by MYC and that both collaborate in the metabolic dysregulation of UC, which has not been mentioned previously. Accordingly, the current work aimed to determine the effect of CEBPD on tumour development and clinicopathological features and to decipher the positive feedback loops driven by the crosstalk between CEBPD and MYC at the genomic, transcriptional and post-transcriptional levels in vitro through quantitative polymerase chain reaction/reverse transcription-polymerase chain reaction (PCR/RT-PCR), western blot, glucose and lactate quantification, cell viability assay, Mito-Red mitochondrial image analysis, Seahorse assays for extracellular acidification rate (ECAR) and oxygen consumption rate (OCR) detection, luciferase reporter assays, and RNA-seq targeting small RNA in two distinct UC cells. In addition, in vivo study via data mining, quantitative RT-PCR, immunohistochemistry (IHC), chromogenic in situ hybridization (CISH), and in situ hybridization targeting microRNA in 635 UC patients and xenografted severe combined immunodeficiency (SCID)/beige mice was conducted. The correlation between UC patient survival and diabetes was validated in a population-based manner in National Health Insurance Research Database (NHIRD).

2 MATERIALS AND METHODS

2.1 Tumour tissue sample sets

In this study, we performed IHC and CISH of well-established sample sets consisting of 295 UBUC and 340 UTUC samples from the biobank of Chi Mei Medical Center. The archived tumour samples were collected after surgery with curative intent between January 1996 and May 2004 as previously described. A total of 32 snap-frozen UC samples with paired non-tumour urothelium were evaluated for CEBPD mRNA and protein expression. This study was approved by the institutional review board of Chi Mei Medical Center (IRB10207-001).

2.2 Reanalysis of aCGH data

Reanalysis of our published aCGH dataset containing 40 UBUC samples was performed by using Nexus Copy Number software (BioDiscovery, USA) as previously described to profile the status of CEBPD and MYC co-amplification. For this analysis, the copy-number gain was defined as log2 ratio >0.2.

2.3 Data mining

We deciphered the correlation between the CEBPD and MYC gene dosages in The Cancer Genome Atlas (TCGA)-bladder cancer (BLCA) dataset and the association between the CEBPD and HK2 gene expression in the GSE13507 dataset through the Oncomine platform (research premium edition).

2.4 Cell culture

Four human UC-derived cell lines including RT4 (American Type Tissue Culture Collection [ATCC], USA), HT1197 (ATCC, USA), TCCSUP (ATCC, USA) and BFTC909 (Food Industry Research and Development Institute, Taiwan) were utilized in this paper. RT4 was incubated in McCoy’s 5A Medium with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin (P/S). HT1197 was maintained in minimum essential media (MEM) with 10% FBS, 1% non-essential amino acid and 1X antibiotic-antimycotic (100X). BFTC909 and TCCSUP were cultured in Dulbecco’s modified eagle medium (DMEM) supplemented with 10% FBS and 1% P/S. All cells were incubated in a humidified incubator containing 5% CO2 at 37°C. The cell culture media, fetal bovine serum and antibiotics were all purchased from Gibco.

2.5 Exogenous gene overexpression in cell lines

Phoenix-AMPHO cells (ATCC, USA) were cotransfected with lentiviral vector contained gene of interest, lentiviral packaging plasmids (psPAX2) and lentiviral envelope plasmid (pMD2.G) dissolved in the Opti-MEM I reduced-serum medium (Gibco) through PolyJet transfection reagents (SignaGen Laboratories). The viral supernatant was harvested 48 h post-transfection. Cell lines were infected with viral particles carrying the target gene and became stable clones through the selection with puromycin (2 μg/ml). Detailed information is shown in Supporting Information.

2.6 Plasmids and oligomers

pLKO-AS3w-eGFP, pLKO-AS3w-CEBPDEGFP and Lenti-MYC-Myc-DDK (RC201611L1, Origene) were used...
for the production of viral particles carrying indicated target genes. pLV-mitoDsRed vector (44386, Addgene, USA) embracing a mitochondrial targeting sequence fused to a recombinant red fluorescent protein (dsRed) was used to detect mitochondrial fission and fusion events. SignalSilence c-Myc small interfering RNAs (siRNAs) (6341, 6552; Cell Signaling Technology, USA) were used for the knockdown of MYC expression. Analysis of promoter activity was conducted by using the following reporters: F-box and WD repeat domain-containing 7 (FBXW7) promoter (S700873; Active Motif, USA), hsa-miR-429-wild-type (WT) promoter-reporter (HPRM 22169-PG04; Genecopoeia), hsa-miR-429-mutant promoter-reporter (TopGen, Taiwan), hsa-miR-429 mimic (TopGen), hsa-miR-429 inhibitor (TopGen), pKM2L-phHKII (RDB05882; Riken, Japan), WT-HK2-3′-untranslated region (UTR) and mutant-HK2-3′-UTR cloned into the pMIR-REPORT Luciferase MicroRNA (miRNA) Expression Reporter Vector contains firefly luciferase (TopGen).

2.7 miRNA sequencing

Note that, 1 μg of total RNA extracted by TRI Reagent RNA Isolation Reagent (Sigma, USA) was used to construct a small RNA library with a TruSeq Small RNA Sample Preparation Kit (Illumina, US) according to its manual instructions. The libraries were applied for sequencing with an Illumina NextSeq sequencer (Illumina, CA, USA). After that, the FASTX-Toolkit (http://hannonlab.cshl.edu/fastx_toolkit) was used for the quality control process. The obtained information was profiled by using miRBase v21 following alignment. An expectation-maximization algorithm was used to normalize miRNA expression data. Finally, the expression level of each miRNA was divided by the total number of aligned reads for precise quantification. The downregulated miRNAs in the CEBPD-overexpressing group with a fold change no less than log2 ratio -1 in at least one cell and log2 ratio exceeding -0.3 in another cell with a significance of p < .05 in duplication tests were selected for further analysis to ensure the significance of the miRNA candidates. The entire protocol was presented in the supplementary materials and methods.

2.8 Real-time quantitative RT-PCR to quantify the mRNA and hsa-miRNA levels

Total RNA extraction from cell lines was utilized by Quick-RNA Miniprep Kit (Zymo Research, CA, USA) according to the manufacturer’s instructions. For the evaluation of mRNA expression, 1 μg of total mRNA was subjected to cDNA synthesis using the Maxima First Strand cDNA Synthesis Kit (Thermo Scientific) with the following thermal cycling steps: 25°C for 10 min, 50°C for 30 min and a final incubation at 85°C for 5 min. The mixture containing cDNA, predesigned TaqMan assay reagent (probe and primer set: CEBPD [Hs00270931_m1], MYC [Hs00153408_m1], FBXW7 [Hs00217794_m1] and HK2 [Hs01034055_g1]; Applied Biosystems) and TaqMan Fast Advanced Master Mix (Applied Biosystems) were subjected to quantitative RT-PCR to determine the mRNA level via a StepOne Plus System (Applied Biosystems) at the indicated thermal cycling: 20 s at 95°C, followed by 40 cycles of 95°C for 1 s and 60°C for 20 s. The cycle threshold (Ct) value of the target gene was normalized to that of the reference gene POLR2A, which served as the ΔCt value. The relative mRNA expression of the target gene to the control gene was estimated using equation 2 − ΔΔCt. For the determination of miRNA expression, a TaqMan Advanced miRNA cDNA Synthesis Kit (Thermo Scientific) was utilized to prepare the cDNA template of miRNA. Afterwards, the mixture of cDNA, predesigned TaqMan assay mixture (probe and primer set targeting hsa-miR-429, U6 snRNA; TopGen) and distilled water were subjected to quantitative RT-PCR in the following thermal cycling conditions: 20 s at 95°C, followed by 40 cycles of 95°C for 1 s and 60°C for 20 s. The relative miRNA level was calculated by the 2 −ΔΔCt formula and U6 snRNA was used as a reference gene. The detailed information was indicated in the supplementary materials and methods.

2.9 Cell viability and cell proliferation assays

2,3-Bis-(2-methoxy-4-nitro-5-sulphonyl) 2H-tetrazolium-5-carboxanilide (XTT) was used to evaluate cell viability. Cells incubated in a 96-well microplate at indicated hours were treated with a mixture of XTT and N-methyl diphenylazobenzene methyl sulfate. Afterwards, the absorbance was measured at a 450 nm wavelength with a reference wavelength at 600 nm in an ELISA reader (GM3000; Promega). Cell proliferation was evaluated by a Cell Proliferation Assay Kit (Fluorometric; Biovision). The fluorescence value proportional to cell number was evaluated at excitation/emission wavelengths of 480/538 nm. The complete procedure is described as Supporting Information.

2.10 Western blot assays

Total protein was isolated using PRO-PREP Protein Extraction Solution (iNtRON). Thirty micrograms of protein were separated on a NuPAGE Bis-Tris Gel (Invitrogen) and
transferred onto an Immobilon-P polyvinylidene difluoride membrane (Millipore). After blocking with skim milk (Sigma), membranes were incubated with indicated primary and appropriate secondary antibodies. Enhanced chemiluminescence (Thermo Scientific) is used for visualizing the proteins of interest.

Primary and secondary antibodies are listed below. Primary antibodies: phospho-MAPK3/1 (Erk1 [pT202/pY204] + Erk2 [pT185/pY187], Abcam, ab50011), MAPK3/1 (Erk1/2) (Cell Signaling, 4695S), phospho-PI3K (Tyr 607, Abcam, ab182651), PI3K (Cell Signaling, 4292S), phospho-AKT (Ser473, Cell Signaling, 4060), AKT (Cell Signaling, 4691), phospho-MTOR (Ser2448, Abcam, ab51044), MTOR (Abcam, ab32028), phospho-RPS6 (Ser235, Abcam, ab80158), RPS6 (Abcam, ab137826), phospho-4E-BP1 (Ser65, Cell Signaling, 9451), 4E-BP1 (Cell Signaling, 9644), caspase-3 (active) (EPITOMICS, 1476-1), FBXW7 (Abcam, ab105752), SKP2 (Abcam, ab124799), MYC (Abcam, ab32072), SLC2A1 (Cell Signaling, ab105752), HK2 (Cell Signaling, 2867), and GAPDH (Abcam, ab181602). Secondary antibody: HRP Donkey anti-rabbit IgG (BioLegend, 406401), HRP goat anti-mouse IgG (Abcam, ab97023). The detailed protocol is exhibited in the Supporting Information.

2.11 Flow cytometric analysis

For cell cycle analysis, harvested cells proceeded to fix by 70% of ethanol at ~20°C overnight. After washing with PBS, cells were resuspended with propidium iodide (PI)/ribonuclease staining buffer (550825; BD Biosciences, USA) protected from light for 15 min at room temperature. The cell cycle distribution was analysed by using a Novo-cyte flow cytometer (ACEA Biosciences, USA). For apoptosis assay, live cells were stained with 5 μl of PI and 5 μl of APC Annexin V (51-66211E, 559925; BD Biosciences) followed by the incubation for 5 min in the dark. The number of apoptotic cells was evaluated by a Novocyt flow cytometer.

2.12 Glucose uptake assays

Glucose uptake was evaluated by a Glucose Uptake Assay Kit (Colorimetric, Abcam). Briefly, glucose transporters of glucose-starved cells were activated by insulin. Note that, 2-deoxyglucose (2-DG), an analogue of glucose, was taken up by glucose transporters and was metabolized to 2-DG-6-phosphate (2-DG6P). Accumulated 2-DG6P in cells is proportional to the amount of glucose uptake by glucose transporters. Note that, 2-DG6P was oxidized to produce NADPH and underwent an enzymatic recycling amplification reaction to generate a coloured product. The absorbances were measured at a wavelength of 405 nm with an ELISA reader (GM3000, Promega). The complete process was presented in the supplementary materials and methods.

2.13 Lactate level analysis

Lactate production was assessed by using an L-lactate assay kit (Colorimetric, ab65331; Abcam). Briefly, the intracellular lactate was extracted from the homogenized cells lysed by the lactate assay buffer and was catalysed by lactate dehydrogenase to produce a material that reacted with a substrate to generate a coloured product. The absorbances were evaluated at a wavelength of 450 nm with an ELISA reader (GM3000; Promega). The detailed procedure is shown in the Supporting Information.

2.14 ECAR and OCR assays

The ECAR and OCR were assessed by an Agilent Seahorse XFp Analyzer (Seahorse Bioscience; USA) according to its manufacturer’s instructions. Briefly, for ECAR assay, cells were seeded in an 8-well cell culture miniplate for 24 h and underwent glucose starvation for 30 min.

Three compounds including glucose, oligomycin, 2-DG were sequentially loaded into the 8-well cell culture miniplate with glucose-starved cells at indicated time point to evaluate the maximal glycolytic capacity based on the value of ECAR. For the OCR test, three reagents containing oligomycin, carbonyl cyanide-p-trifluoromethoxyphenylhydrazone and rotenone/antimycin A were orderly injected into cells seeded into an 8-well miniplate to directly evaluate the OCR of cells. The complete method is indicated as Supporting Information.

2.15 Luciferase reporter assays

The FBXW7 promoter-reporter (optimized Renilla luciferase) or pGL4.54[luc2/TK] vector (firefly luciferase) was transfected into cells by using PolyJet In Vitro DNA Transfection Reagent according to its protocol. The activity of optimized Renilla luciferase and firefly luciferase were assessed by LightSwitch Luciferase Assay Kit (Active Motive) and ONE-Glo Luciferase Assay System (Promega) according to manufacturer’s instruction (Supporting Information), respectively.

The Renilla luminescence value was normalized by the firefly luminescence value and represented the activity of the FBXW7 promoter.
The hsa-miR-429 promoter activity was conducted under a dual-reporter system comprising an hsa-miR-429 promoter with gaussian luciferase (GLuc) reporter and a secreted alkaline phosphatase (SEAP) reporter served as an internal control. After transfection of the hsa-miR-429 promoter dual-reporter in cells, the activity of secreted GLuc and SEAP was detected by Secrete-Pair Dual Luminescence Assay (Genecopoeia) in line with the manufacturer's instructions.

Firefly luciferase reporter vector containing WT-HK2-3′-untranslated region (UTR) or mutant-HK2-3′-UTR was cotransfected with pGL4.74[hRluc/TK] into cells. The luminescence signal was measured by a Dual-Glo Luciferase Assay System (Promega) according to the manufacturer's instructions. The firefly luminescence units were normalized by the Renilla luminescence units to reflect the activity of each HK2-3′-UTR reporter.

Mock- and CEBPD-overexpressing cells were cotransfected with pKM2L-phHKII (Renilla luciferase) and pGL4.54[luc2/TK] vectors, followed by the treatment of hsa-miR-429 mimic or control mimic. The luminescence signal was measured by a Dual-Glo Luciferase Assay System (Promega). Finally, the Renilla luminescence units were normalized by the firefly luminescence units to indicate HK2 promoter activity. Complete information above is shown in Supporting Information.

### 2.16 Analysis of copy number variation by qPCR

Genomic DNA was extracted using the QIAamp DNA Mini Kit (Qiagen) according to the manufacturer’s instructions. The mixture including genomic DNA, TaqMan SNP Genotyping Assay probes (PIK3R1, Hs06028467_cn; CEBPD, Hs01845884_cn; Hs01879749_cn; Hs02239340_cn) and TaqMan Genotyping Master Mix (Applied Biosystems) was subjected to quantitative RT-PCR under StepOne Plus System. The thermal cycling conditions were as follows: 10 min at 95°C, followed by 40 cycles of 95°C for 15 s and 60°C for 1 min. The Ct value of CEBPD was normalized to that of the PIK3R1 (reference gene), and this value was defined as ΔCt. Relative quantification (RQ) was performed by using the 2−ΔΔCt formula, and the copy number was represented as 2×RQ.

### 2.17 Next-generation sequencing-based loss of heterozygosity analysis

To further elucidate whether MYC expression enhances CIN, which is assumably the causal factor of CEBPD amplification, we use next-generation sequencing (NGS)-based ACTHRD panel (ACT Genomics) to measure the loss of heterozygosity (LOH) in cell lines. For this assay, genomic DNA from cells was extracted and amplified using primer pairs targeting coding exons of 24 homologous recombination repair (HRR)-related genes (Table S1) and 8833 single nucleotide polymorphisms (SNPs) evenly distributed across the entire genome. After library preparation, the product was sequenced and analysed for mutations, copy number variations, and LOH (Supporting Information).

### 2.18 Chromatin immunoprecipitation

A SimpleChIP Enzymatic Chromatin IP Kit (Cell Signaling) was used for chromatin immunoprecipitation (ChIP) assay. Briefly, fragmented cross-linked chromatin extracted from cells was immunoprecipitated with primary antibody against CEBPD (Santa Cruz, sc-365546) and protein G magnetic beads at 4°C. Afterwards, the precipitated DNA was purified from the antibody/protein G complex and was subjected to quantitative RT-PCR under the thermal cycle: 3 min at 95°C, followed by 40 cycles of 95°C for 15 s and 60°C for 1 min. The primers targeting CEBPD-responsive element binding site on the hsa-miR-429 promoter were shown as below: forward: 5′-GGTTCTTCCCTGGGCTTC-3′; reverse: 5′-AGTGTTAGATCAAGCTGGGAAAT-3′.

### 2.19 High-throughput chromosome conformation capture

To systematically explore the possibility of long-range regulation of the MYC gene on CEBPD, we evaluate the CEBPD-interacting genes using the high-throughput chromosome conformation capture (Hi-C) technique. We performed Hi-C on both BFTC909 and TCCSUP cells using the Arima Hi-C Kit (A510008; Arima Genomics, USA). Hi-C experiments were performed as previously described.24 The library generated was submitted to a NextSeq 2000 for sequencing. Raw sequencing data were mapped and processed to the UCSC Hg19 reference genome using HiC-Pro v3.1.0 pipeline,25 and restriction fragment BED file was generated by using digest_genome.py script from HiC-Pro utilities. The R package HiTC26 was used to perform data normalization and to visualize the interaction map.

### 2.20 Immunohistochemistry

Formalin-fixed, paraffin-embedded (FFPE) tissue sections were deparaffinized and rehydrated by using xylene and ethanol, respectively. After retrieval with citrate buffer
at pH 6.0, the endogenous peroxidase activity of specimens was quenched by peroxidase-blocking solution (Dako). The sections were incubated with the primary antibody against the target protein as indicated below: MYC (Abcam, ab32072), CEBPD (Abcam, ab184911), HK2 (Cell Signaling, 2867), FBXW7 (Abcam, ab105752), phospho-AKT (Cell Signaling, 4060), phospho-mTOR (Abcam, ab51044), phospho-4E-BP1 (Cell Signaling, 9644), phospho-RPS6 (Abcam, ab80158), and MKI67 (Abcam, ab66155), followed by the incubation of a secondary antibody REAL EnVision/HRP, rabbit/mouse [ENV], Dako). Staining was visualized with EAL DAB+ Chromogen diluted in REAL Substrate Buffer (Dako). Hematoxylin was used for the nuclear stain. Finally, the slices were dehydrated by soaking in various concentrations of ethanol and were mounted in UltraCruz Aqueous Mounting Medium with DAPI. The IHC staining results were examined with an optical microscope and quantified into H-scores by three expert pathologists (Chien-Feng Li, Tzu-Ju Chen and Wan-Shan Li) as previously mentioned. Detailed information is shown in Supporting Information.

2.21 Chromogenic in situ hybridization

The human MYC gene was detected by a CISH assay. Briefly, FFPE slides were deparaffinized and rehydrated by xylene and ethanol. After the treatment with 0.2 N hydrochloric acid, the slides were soaked with pretreatment buffer followed by pepsin dissolved in protease buffer. The slides were dehydrated with various concentrations of ethanol following the fixed with 4% paraformaldehyde.

The slides were incubated with ZytoDotSPEC MYC probe overnight and were targeted with anti-digoxigenin antibody (NBP2-31191; Novus). The signal of MYC locus was visualized using EAL™ DAB+ Chromogen diluted in REAL Substrate Buffer (Dako). Hematoxylin was used for the nuclear stain. The dehydation, mounting process and detailed process are described as Supporting Information.

2.22 In situ hybridization detection of miRNAs

The IsHyb In Situ Hybridization Kit (BioChain) was used to detect the level of hsa-miR-429 according to the manufacturer’s instructions. Briefly, the FFPE slides proceeded to the process of deparaffinization and dehydration. After the fixation of 4% Diethyl pyrocarbonate (DEPC)-paraformaldehyde, the slices were treated with a prehybridization solution followed by the incubation of digoxigenin-labeled RNA oligo probe against hsa-miR-429 (Exiqon). The signal of hsa-miR-429 was visualized following the incubation with AP-conjugated anti-digoxigenin antibody and a mixture of nitro-blue tetrazolium and 5-bromo-4-chloro-3-indolyl phosphate (BCIP). The nuclear Fast Red solution (Sigma) was used for the nuclear counterstaining. Mounting, dehydration and detailed procedures were indicated in Supporting Information.

2.23 Xenograft animal models

SCID/beige male mice were purchased from BioLASCO (Taiwan). The animal study was approved by the Institutional Animal Care Committee of Chi-Mei Medical Center (Approval number 109041701). After one week of feeding the normal diet (OYDMFG22; BioLASCO, Taiwan), two of these four groups were switched to a high-fat diet regimen (58Y1; TestDiet) for the duration of the study to induce type 2 diabetes mellitus (DM), as described in previous research.27 The body weight and fasting blood glucose of mice were robustly increased upon switching to a high-fat diet (Figure S1). Mock- or CEBPD-overexpressing BFTC909 cells mixed with high-concentration Matrigel (354248; Corning Life Sciences, USA) were injected subcutaneously into groups with normal diet or high-fat diet. The tumour diameters were measured at the indicated time using callipers and calculated by the following equation: V (mm$^3$) = ($\pi/6$) × width (mm$^2$) × length (mm). The mice were sacrificed with asphyxiation. The tumours were dissected and fixed in 10% formalin for further analysis.

2.24 Analysis of data from the NHIRD

We conducted a population-based longitudinal observational cohort study in Taiwan from 2000 to 2010 to analyse whether DM comorbidity impacts the prognosis of UBUC and UTUC by using the NHIRD database. Catastrophic illness registry data were also included in this database, and comorbidity information of patients was collected. The inclusion criteria of the BLCA cohort group were as follows: age over 20 years old and UBUC diagnosis (International Classification of Disease [ICD]-9 code 188.9) from 2000 to 2008 or UTUC diagnosis (ICD-9 code 189.1 or 189.2). The exclusion criteria were as follows: age less than 20 years and incomplete demographic data. From both our BLCA and UTUC groups, patients with simultaneous DM (ICD-9 code 250.X0 and 250.X2) were identified. After matching age, sex, index year, and all comorbidities, we included three times the number of patients without DM to use as a comparison group. The diagnosed comorbidities
included chronic kidney disease (CKD) (ICD-9 code 580–589), hypertension (ICD-9 code 401–405), chronic obstructive pulmonary disease (COPD) (ICD-9 code 490–496), stroke (ICD-9 code 430–438), cardiovascular disease (ICD-9 code 410–414), peripheral vascular disease (ICD-9 code 250.7, 785.4, 443.81, 440–448), hyperlipidemia (ICD-9 code 272.0–272.4), urinary tract disease (ICD-9 code 590–599), and benign prostatic hyperplasia (ICD-9 code 600).

2.25 Statistics

The correlations and associations between targeted genes or proteins and clinicopathologic variables, as well as comparisons for various functional and animal studies, were evaluated by Spearman’s rank correlation coefficient, Chi-square test, or Mann-Whitney U test as appropriate by using SPSS software (version 14.0; IBM, USA). Disease-specific survival (DSS) and metastasis-free survival (MeFS) were estimated and plotted by means of log-rank tests and Kaplan-Meier curves, respectively. A multivariate Cox proportional hazards model was used to evaluate the independent prognostic impacts of selected parameters. Kaplan-Meier curves were drawn and the cumulative survival rate and log-rank statistic for the NHIRD data were assessed by using SAS version 9.3 (SAS Institute, Cary, NC). Both univariate and multivariate Cox proportional hazards regressions were performed after adjusting for comorbidities to measure the risk of UBUC and UTUC. For all analyses, differences with a two-tailed p-value lower than .05 were considered significant.

3 RESULTS

3.1 CEBPD confers mTORC1-driven metabolic reprogramming and glucose addiction in UC

To clarify the oncogenic property of CEBPD, the expression of CEBPD on clinical specimens was examined. A higher level of CEBPD transcript was observed in the UCs compared to their non-tumour counterparts. Particularly, the mRNA level of CEBPD showed a stepwise escalation from non-tumour urothelium, non-muscle invasive bladder cancer (NMIBC), to muscle invasive bladder cancer (MIBC) (NMIBC vs. Normal, p < .001; MIBC vs. Normal, p = .048; MIBC vs. NMIBC, p = .006; Figure S2A). Consistently, UC specimens also represented higher CEBPD protein levels than non-tumour urothelium (Figure S2B). In the following experiments, we utilized four UC-derived cell lines (RT4, HT1197, BFTC909 and TCCSUP) to explore the molecular mechanism underlying the poor prognostic impact of CEBPD. BFTC909 and TCCSUP cells had the lowest level of CEBPD (Figure 1A); therefore, CEBPD overexpression was induced in these cell lines. Compared to lentiviral infection with the mock sequence, lentiviral infection with the CEBPD gene significantly increased the mRNA and protein levels of CEBPD in BFTC909 and TCCSUP cells (Figure 1B,C). We previously identified that overexpression of CEBPD contributes to increased cell viability in UC-derived cell lines.28 Furthermore, higher cell proliferation was also observed in CEBPD-overexpressing BFTC909 and TCCSUP cells than in mock-transfected BFTC909 and TCCSUP cells (Figure 1D).

Given that mTOR is a master regulator of cell growth,29,30 the potential correlations between CEBPD and mTOR signalling-related proteins were examined. The phosphorylation levels of mTOR and its upstream activators, including MAPK3/1, PI3K, and AKT1, as well as downstream regulators, including RPS6 and EIF4EBP1, were notably upregulated, while the expression level of cleaved CASP3, a marker of apoptosis, was downregulated in CEBPD-overexpressing BFTC909 and TCCSUP cells (Figure 2A). Moreover, increased expression of CEBPD promoted the expression of S-phase kinase-associated protein 2 (SKP2) (Figure 2A), which is an E3 ubiquitin ligase that activates AKT1 through the ubiquitination process.30 The above data suggest that CEBPD activates mTOR downstream targets through MAPK3/1- and PI3K/AKT-dependent pathways.

mTOR signalling is one of the major hubs of the glucose-sensing pathway, and large amounts of glucose are essential for tumour progression. Glucose deprivation is related to the inhibition of mTORC1 activity, anabolic processes, cell proliferation and the cause of cell death.31–33 Therefore, the impact of CEBPD on the cell survival and downstream regulation of the mTOR pathway under glucose-deprived conditions was examined. The cell viability of mock-infected BFTC909 and TCCSUP was notably decreased after glucose deprivation (Figure 2B). However, CEBPD overexpression exacerbated glucose deficiency-induced cell viability inhibition (Figure 2B). CEBPD overexpression also failed to induce the increased pAKT1, pMTOR, pRPS6, pEIF4EBP1 and SKP2 after the glucose deprivation in these two distinct UC cells. (Figure 2C). Nevertheless, the effects of glucose deprivation on pMAPK3/1 and pPI3K protein levels were not comparable in CEBPD-overexpressing BFTC909 and TCCSUP cells. Cleaved CASP3 was upregulated under glucose-deficient conditions in both CEBPD-overexpressing cell lines. In cell cycle analysis, exogenous CEBPD inhibited the sub G1 fraction in the BFTC909 and TCCSUP treated with general culture medium (Figure S3A,B,E–G,J). Reversely, CEBPD overexpression increased a sub G1 population in cells under glucose deprivation than in mock-group
Overexpression of CCAAT/enhancer-binding protein delta (CEBPδ) confers a pro-proliferative phenotype in BFTC909 and TCCSUP cells. Quantitative reverse transcription-polymerase chain reaction (RT-PCR) and immunoblotting (A) showed that the transcript and protein levels of CEBPD were lower in the BFTC909 and TCCSUP cells among the four urothelial carcinoma (UC)-derived cell lines. Hence, Exogenous CEBPD expression was performed in BFTC909 and TCCSUP cells to examine the biological impact of CEBPD on tumorigenesis. The mRNA (B) and protein (C) levels of CEBPD were significantly upregulated in BFTC909 and TCCSUP cells after successful exogenous expression of the CEBPD gene compared with the mock-transfected cell lines. (D) Proliferation assay showed that overexpression of CEBPD in BFTC909 and TCCSUP significantly increased pro-proliferative phenotype at 24–72 hours after seeding compared to the mock-transfected cells. All experiments were conducted in triplicate and results were represented as the mean ± SEM. For immunoblot assay, one representative image was shown and GAPDH was regarded as a loading control. Statistical significance: *p < .05

(Figure S3C–E,H–J). Additionally, exogenous CEBPD also led to S phase arrest in the glucose-deprived BFTC909 and TCCSUP (Figure S3C–E,H–J). The distribution of cells in the G1 or G2 phase was not comparable in mock- and CEBPD-infected BFTC909 and TCCSUP treated with general culture medium or glucose deprivation (Figure S3). Annexin V/PI assay showed the apoptotic cells were mildly decreased after CEBPD overexpression in BFTC909 and TCCSUP (Figure S4A,B,E–G,J) while were drastically escalated in CEBPD-infected cells with glucose removal (Figure S4C,D,H–J). These data suggested that UC-derived cell lines with CEBPD overexpression are more susceptible to glucose deprivation (i.e., these cells exhibit glucose addiction) and could result in the suppression of mTORC1 activity, retarded cell proliferation and increased apoptosis.

We next aimed to examine the effect of exogenous CEBPD overexpression in BFTC909 and TCCSUP cells on cell metabolism. Compared with the mock-transfected cells, CEBPD-overexpressing BFTC909 and TCCSUP cells showed increases in glucose uptake (Figure 2D), cellular lactate production (Figure 2E), and the ECAR (Figure 2F), a decrease in the cellular OCR (Figure 2G), and a shift from mitochondrial fusion to fission (Figure 2H). These findings suggest that CEBPD-overexpressing cells undergo glycolysis and a metabolic switch from mitochondrial respiration to aerobic glycolysis.

Increased glycolysis is inevitably driven by the upregulation of the glycolysis-related gene profile which consists of solute carrier family 2 member 1 (SLC2A1, also known as glucose transporter 1, GLUT-1) and Hexokinase 2 (HK2) as the major elements. Of these, HK2, which encodes the enzyme that catalyses the formation of glucose 6-phosphate (G6P) from glucose in the first step in glycolysis, is a critical regulator of aerobic glycolysis. Accordingly, we tried to explore whether the preference of oxidative phosphorylation (OXPHOS) to aerobic glycolysis promoted by CEBPD is linked to the dysregulation of glycolysis-related gene profile, with special attention to HK2 expression. An analysis of BLCA specimens in the Gene Expression Omnibus Database (GSE13507 dataset, n = 188) using the Oncomine Research Premium Edition tool (http://oncomine.org) revealed a marked positive correlation between the mRNA levels of CEBPD and HK2 (r = 0.324, p < .001; Figure 2I). We then examined the mRNA level of these two genes in BFTC909 and TCCSUP cells, and the mRNA level and promoter activity of HK2 were increased upon CEBPD overexpression (Figure 2J,K). Western blotting showed that the overexpression of exogenous CEBPD markedly elevated the protein levels of HK2 and SLC2A1 but not that of lactate dehydrogenase A/C (LDH A/C) in BFTC909 and TCCSUP cells (Figure 2L), indicating that CEBPD increases the expression of SLC2A1 and HK2 to meet the demands of rapid glycolytic flux.
CCAAT/enhancer-binding protein delta (CEBPδ) overexpression confers mTORC1-driven metabolic reprogramming and leads to glucose addiction. The potential relationship between CEBPδ and proteins associated with the mTOR pathway was explored by immunoblotting analysis. (A) pMAPK3/1, pPI3K, pAKT1, pMTOR, pRPS6, pEIF4EBP1 and SKP2 were significantly upregulated, while cleaved CASP3 was notably decreased in CEBPδ-overexpressing BFTC909 and TCCSUP cells treated with culture medium containing glucose compared to mock-expressing cells. (B) 2,3-Bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide (XTT) assay indicated that cell viability was notably inhibited in mock-expressing BFTC909 and TCCSUP cells under glucose starvation (culture medium without glucose) for 72 h compared to mock-expressing cells in a complete cell culture medium. Furthermore, CEBPδ overexpression further exacerbated glucose withdrawal-induced cell viability suppression in these two cell lines. (C) Immunoblotting data indicated that glucose deficiency suppresses the effect of CEBPδ on the upregulation of pAKT1, pMTOR, pRPS6, pEIF4EBP1 and SKP2 protein and the downregulation of CASP3 in these two distinct UC-derived cells. However, the protein levels of pMAPK3/1 and pPI3K were not comparable in CEBPδ-overexpressing BFTC909 and TCCSUP cells under glucose starvation conditions. Glucose uptake assay (D), lactate level analysis (E), Seahorse XFp Analyzer assessment (F–G), OCR, and MitoDsRed-tagged fluorescent mitochondrial staining (H) were performed to evaluate...
These data disclosed that CEBPD enhances glucose influx through the upregulation of SLC2A1 and HK2 to fuel the mTOR signalling under glucose addiction which is conferred by the metabolic reprogramming from mitochondrial respiration to aerobic glycolysis triggered by mTOR signalling.

3.2 Positive crosstalk between CEBPD and MYC in UC

MYC has been also elucidated to involve in the upregulation of key glycolysis-related genes including SLC2A1 and HK2, therefore, it appeared that some kind of interplay between CEBPD and MYC on glycolysis. To clarify the correlation between CEBPD and MYC, we reanalysed our previously published aCGH data, aside from the amplification of CEBPD, copy number gain (CNG) of the MYC, which is also mapped to chromosome 8q24.21, was also preferentially detected in UBUC patients who experienced disease-specific death (69.23% vs. 18.52% in patients with no events, \( p = .0034 \)) and distal metastasis (75.0% vs. 8.33% patients with no events, \( p < .0001 \)) and was highly associated with CEBPD CNG (\( p < .001 \)) (Table S2). Reassessment of the TCGA dataset through the Oncomine platform showed that 32.2% (49/152) and 46.7% (71/152) of UBUC samples had CNGs (log2 ratios \( \geq 0.2 \)) involving CEBPD and MYC, respectively, and there was a significant positive correlation between the CEBPD and MYC gene dosages (\( r = 0.427, p < .001 \)) (Figure 3A and Figure S5). Moreover, there was a significant positive correlation between CEBPD and MYC transcript expression in UBUC (GSE13507, \( n = 188, r = 0.477, p < .001 \)) (Figure 3B and Figure S6). By using fluorescence in situ hybridization, CISH and IHC, we also identified significant positive correlations between CEBPD CNG/expression and MYC CNG/expression in our UBUC and UTUC cohort (Tables 1 and 2). Nevertheless, CEBPD overexpression in BFTC909 and TCCSUP cells did not induce MYC CNG (Figure 3C), but elevated CEBPD CNG was observed upon MYC overexpression (Figure 3D), implying that MYC overexpression precedes CEBPD CNG and that overexpression is probably driven by MYC-mediated chromosomal instability (CIN).

To determine whether MYC enhances chromosomal instability, we compared the LOH of cell lines with and without exogenous MYC overexpression using the targeted NGS approach. Interestingly, with the targeted NGS focusing on 24 HRR-related genes, we identified several mutations in the parental BFTC909 cell including BRIP1 p.N196S (VUS), BRCA1 exon 1–3 replication, and CDK12 heterozygous deletion (Tables S3 and 4) but none in the parental TCCSUP cell. Accordingly, we used the TCCSUP cell as a model to computerize MYC-enhancing chromosomal instability to avoid confounders. The analysis of heterozygous SNPs showed that MYC overexpression leads to a 17.5% and 9.0% increase in the genomic LOH in the BFTC909 and TCCSUP cell lines, respectively. (Table S5). The above-mentioned findings suggested MYC can drive CIN in UC that probably the causal factor of MYC-associated CEBPD gain in UC.

To systematically exclude the possibility that MYC upregulates CEBPD directly through long-range chromatin interaction, we performed NGS-based Hi-C experiments. The Capture Hi-C were processed using HiC-Pro pipeline, the raw contact frequency was normalized using iterative correction and eigenvector decomposition method, and the normalized interactions map were visualized at 40 kb bin size resolution using the HiTC R package (Figure S7), which showed there are no predicted intra-TAD loops between CEBPD and MYC gene in both TCCSUP and BFTC909 cells.

The expression of MYC is not always proportional to the level of the MYC dosage in UC. In line with the previous study, we also found that 37.9% (22 out of 58) of MYC-amplified UBUCs and 12.1% (7 out of 58) of MYC-amplified UBUCs showed low MYC expression, while 20.7% (49 out of 237) of MYC-nonamplified UBUCs and 8.5% (24 out of 282) of MYC-nonamplified UTUCs showed high MYC expression (Tables 1 and 2 and Figure 3E), suggesting that amplification-independent
Collaboration of CCAAT/enhancer-binding protein delta (CEBPd) and MYC in the regulation of SLC2A1 and HK2. (A) To assess the crosstalk between the dosage/gene expression of CEBPd and MYC, we reassessed The Cancer Genome Atlas (TCGA) bladder cancer dataset and found that 32.2% (49/152) and 46.7% (71/152) of urothelial carcinomas (UCs) showed copy number gains (CNGs) involving CEBPd and MYC, respectively. Moreover, a notably positive correlation (45/152, $r = 0.427$, $p < .001$) between CEBPd and MYC dosage was observed. The Red dashed line indicated the log2 ratio of 0.2, which represent the cut-off of copy number gain. (B) Assessment of the GEO database (GSE13507 dataset, $n = 188$) identified a markedly positive relation between the transcript levels of MYC and CEBPd ($r = 0.477$, $p < .001$). Copy number variation (CNV) profiled by real-time PCR using three distinct probes targeting three different regions of the MYC and CEBPd chromosomes indicated that the overexpression of MYC through viral delivery systems could induce CEBPd amplification in BFTC909 and TCCSUP (D) cells but not vice versa (C). (E) Immunohistochemistry (IHC; left) and chromogenic in situ hybridization (CISH; right) assays revealed an inconsistency between the expression and gene dosage of MYC in a representative case of UTUC with MYC amplification but a low MYC expression. (F) The effect of CEBPd overexpression on the promotion of MYC transcription was not comparable.
mechanisms regulate MYC expression. In vitro, we also identified that the amount of upregulated MYC protein in CEBPD-overexpressing BFTC909 and TCCSUP is not comparable to those of the mRNA level (Figure 3F,G), which indicates that CEBPD proceeds through an alternative pathway apart from transcriptional regulation to manage MYC expression. Therefore, the effect of CEBPD on MYC protein stability was measured using a cycloheximide (CHX) assay. Compared to that in mock-transfected cells, the half-life of endogenous MYC protein after treatment with CHX in CEBPD-overexpressing BFTC909 and TCCSUP cells was notably prolonged (Figure 3H,I). Furthermore, the ubiquitin-proteasome inhibitor MG132 significantly prevented the degradation of the MYC protein in the mock-transfected cells compared with the vehicle-treated mock-transfected cells, but the effect of MG132 on the MYC protein level was mild in CEBPD-overexpressing cells (Figure 3J). Based on the above findings, CEBPD could stabilize MYC protein expression by protecting MYC from ubiquitin-mediated proteasomal degradation instead of regulating the transcription of the MYC gene.

Next, given that FBXW7, a critical substrate recognition component of the SKP1-CUL1-F-box protein (SCF) E3 ubiquitin-protein ligase complex that mediates proteasomal degradation through phosphorylation-dependent ubiquitination, is well known to target important oncoproteins such as MYC,12,13 we next clarified whether CEBPD stabilizes MYC by inhibiting FBXW7. The mRNA and protein levels of FBXW7 and the FBXW7 promoter activity were strikingly decreased after CEBPD overexpression in BFTC909 and TCCSUP cells (Figure 3K–M), suggesting that CEBPD directly suppresses FBXW7 through transcriptional regulation. These data indicate that chromosomal instability of MYC and CEBPD is concomitant and represents a positive correlation in UC. We also disclosed that there is a potent positive feedback loop between MYC and CEBPD to collaboratively regulate oncogenesis: Upregulated expression of CEBPD following the CEBPD amplification could be subsequent to the MYC-dependent genome instability. In addition, increased CEBPD also displayed a protective role to stabilize the protein level of MYC through the inhibition of the FBXW7-mediated proteasomal degradation.

### 3.3 | CEBPD promotes the level of HK2 via inhibition of hsa-miR-429 and is partially independent of MYC regulation

To evaluate the cooperative regulation of CEBPD and MYC on glycolytic-related genes, the protein level of SLC2A1 and HK2 was examined after the CEBPD overexpression or/and the treatment of the MYC siRNAs. The protein levels of SLC2A1 and HK2 were elevated after CEBPD overexpression in BFTC909 and TCCSUP cells but were partially downregulated after transfection of cells with two distinct MYC siRNAs (siMYC1 and siMYC2) which substantially depleted the protein level of MYC (Figure 4A), indicating that CEBPD could also induce glycolysis-related protein expression in MYC-independent manners. Accordingly, other potential mechanisms by which CEBPD regulates the glycolytic pathway were further examined by RNA-seq. In total, Top 7 miRNAs met the selection criteria (log2 ratio < 0.5 in both cell lines). hsa-miR-429 was the most significantly downregulated in BFTC909 cells (log2 ratio -1.985) and was also significantly downregulated in TCCSUP cells (log2 ratio -0.439) as well as the most remarkable mean fold change (log2 ratio -1.2127) (Table S6). As hsa-miR-429 has been previously predicted to target the HK2 gene based on the target-prediction algorithm from miRanda (http://cbio.mskcc.org/miRNA2003/miranda.html), we then clarified the correlation between CEBPD and hsa-miR-429 and its relation to glycolysis. In silico analysis revealed one putative CEBPD binding site at the promoter of hsa-miR-429 (Figure 4B, based on http://jaspar.genereg.net/). Interestingly, not only HK2 (Figure 4C) but also CEBPD and MYC were predicted or validated as potential targets of hsa-miR-429 by miRanda. Therefore, we first confirmed that the CEBPD and MYC transcripts were not altered by hsa-miR-429 in BFTC909 and TCCSUP cells (Figure 4D,E). Subsequently,
| Parameter                        | Category       | Case No. | MYC amplification | MYC expression | miR-429 expression | HK2 expression |
|---------------------------------|----------------|----------|-------------------|----------------|-------------------|---------------|
|                                 |                |          | Non-amp | Amp | p-value | Low | High | p-value | Low | High | p-value | Low | High | p-value | Low | High | p-value |
| Sex*                            | Male           | 216      | 175     | 41  | .627     | 153 | 63   | .825     | 138 | 78   | .262     | 165 | 51   | .937     |
|                                 | Female         | 79       | 62     | 17  | .510     | 57  | 22   | 126     | 48  | 115   | 59     | 113 | 43   |
| Age (years)                     | <65            | 121      | 95     | 26  | .944     | 84  | 37   | .577     | 79  | 42   | .886     | 94  | 27   | .634     |
|                                 | ≥65            | 174      | 142    | 32  | 138      | 78  | 63   | 138      | 78  | 63   | 138      | 78  | 63   |
| Diabetes mellitus*              | Negative       | 240      | 193    | 47  | .944     | 169 | 71   | .542     | 154 | 86   | .288     | 165 | 54   | .300     |
|                                 | Positive       | 55       | 44     | 11  | 14      | 40  | 15   | 118      | 59  | 118   | 59     | 118 | 59   |
| Primary tumor (T)*              | Ta             | 84       | 84     | 0   | <.001*   | 79  | 5    | <.001*   | 20  | 64   | <.001*   | 80  | 4    | <.001*   |
|                                 | T1             | 88       | 82     | 6   | 72       | 16  | 6    | 59       | 64  | 118   | 59     | 113 | 43   |
|                                 | T2–T4          | 123      | 71     | 52  | 41       | 14  | 6    | 40       | 14  | 14    | 14     | 14  | 14   |
| Nodal metastasis*               | Negative (N0)  | 266      | 222    | 44  | <.001*   | 198 | 68   | <.001*   | 166 | 100  | <.001*   | 212 | 54   | <.001*   |
|                                 | Positive (N1–N2)| 29       | 15     | 14  | 12       | 17  | 14   | 28       | 1   | 13    | 16     | 13  | 16   |
| Histological grade*             | Low grade      | 56       | 55     | 1   | <.001*   | 48  | 8    | .008*    | 15  | 41   | <.001*   | 50  | 6    | .011*    |
|                                 | High grade     | 239      | 182    | 57  | 162      | 77  | 6    | 179      | 60  | 175   | 64     | 175 | 64   |
| Vascular invasion*              | Absent         | 246      | 207    | 39  | <.001*   | 190 | 56   | <.001*   | 147 | 99   | <.001*   | 197 | 49   | .001*    |
|                                 | Present         | 49       | 30     | 19  | 20       | 17  | 19   | 47       | 2   | 28    | 21     | 28  | 21   |
| Perineural invasion*            | Absent         | 275      | 225    | 50  | .018*    | 203 | 72   | <.001*   | 174 | 101  | .001*    | 214 | 61   | .021*    |
|                                 | Present         | 20       | 12     | 8   | 7        | 13  | 7    | 20       | 0   | 9     | 9      | 9   | 9    |
| Mitotic rate (per 10 high power fields)* |        | 295      | 13.8   | 16.8 | .035*    | 13.7 | 16.4 | .013*    | 16.1 | 11.1 | <.001*   | 13.2  | 18.3 | <.001*   |
|                                 |                |          | +/-14.22 | +/-13.11 | | +/-14.51 | +/-12.66 | | +/-13.39 | +/-14.70 | | +/-14.15 | +/-13.02 |
| CEBPD gene amplification*       | Non-amp        | 232      | 208    | 24  | <.001*   | 199 | 33   | <.001*   | 135 | 97   | <.001*   | 204  | 28   | <.001*   |
|                                 | Amp            | 62       | 29     | 34  | 11       | 52  | 5    | 59       | 4   | 21    | 42     | 21  | 42   |
| CEBPD expression*               | Low expression | 207      | 187    | 20  | <.001*   | 193 | 14   | <.001*   | 117 | 90   | <.001*   | 197  | 10   | <.001*   |
|                                 | High expression | 88       | 50     | 38  | 17       | 71  | 14   | 11       | 11  | 28    | 60     | 28  | 60   |
| MYC amplification*              | Non-amp        | 237      | 188    | 49  | <.001*   | 140 | 97   | <.001*   | 195 | 42   | <.001*   | 30   | 28   | .001*    |
|                                 | Amp            | 58       | 22     | 36  | 11       | 54  | 4    | 11       | 11  | 33    | 52     | 33  | 52   |
| MYC expression*                 | Low expression | 210      | 155    | 55  | <.001*   | 115 | 95   | <.001*   | 192 | 18   | .001*    | 33   | 28   | .001*    |
|                                 | High expression | 85       | 79     | 6   | 11       | 33  | 28   | 131      | 63   | 131   | 63     | 131 | 63   |
| miR-429 expression*             | Low expression | 194      | 131    | 63  | <.001*   | 18  | 52   | <.001*   | 131 | 63   | <.001*   | 131  | 63   | <.001*   |
|                                 | High expression | 101      | 94     | 7   | 11       | 67  | 54   | 94       | 7   | 94    | 7      | 94  | 7    |

* Chi-square test.
* Mann-Whitney U test; all other comparisons.
* Statistical significance. Tumour samples were taken from the biobank of Chi Mei Medical Center.
**TABLE 2** Correlations between CCAAT/enhancer-binding protein delta (CEBPD) and MYC amplification/expression and miR-429 and HK2 expression and other important clinicopathological parameters in upper urinary tract urothelial cancer (UTUC)

| Parameter | Category | Case No. | MYC amplification | MYC expression | miR-429 expression | HK2 expression |
|-----------|----------|----------|-------------------|---------------|-------------------|---------------|
|           |          |          | Non-amp | Amp | p-value | Non-amp | Amp | p-value | Non-amp | Amp | p-value | Non-amp | Amp | p-value |
| Sex*      | Male     | 158      | 129     | 29  | .554    | 122     | 36  | .763    | 117     | 41  | .539    | 119     | 39  | .640    |
|           | Female   | 182      | 153     | 29  |         | 143     | 39  |         | 140     | 42  |         | 141     | 41  |         |
| Age (years) ≥65 | 202 | 170 | 32 | .470 | 158 | 44 | .033* | 161 | 41 | .640 | 158 | 44 | .640 |
|           | <65      | 138      | 112     | 26  | .768    | 107     | 31  | .033*  | 96      | 42  | .358    | 102     | 36  | .358    |
| Diabetes mellitus Negative | 276 | 230 | 46 | .690 | 216 | 60 | .768 | 202 | 74 | .032* | 212 | 64 | .758 |
|           | Positive | 64       | 52      | 12   |         | 49      | 15   |         | 55      | 9   |         | 48      | 16  |         |
| Multifocality Single | 273 | 231 | 47 | .874 | 219 | 59 | .431 | 206 | 72 | .176 | 215 | 63 | .425 |
|           | Multifocal | 62   | 51     | 11   |         | 46      | 16   |         | 51      | 11  |         | 45      | 17  |         |
| Primary tumor (T) T1 | 92  | 83     | 9      | .003* | 79  | 13    | 88    | 4      | 83      | 9   |         | 83      | 9    |         |
|           | ≥T2–T4 | 159     | 117    | 42   | .039*  | 102     | 57   | .032*  | 131     | 28  | .033*   | 102     | 57  | .033*   |
| Nodal metastasis Negative (N0) | 312 | 267 | 45 | .001* | 254 | 58 | .001* | 232 | 80 | .078  | 246     | 66  | .001*   |
|           | Positive (N1–N2) | 28  | 15     | 13   | .003*  | 11      | 17   | .003*  | 25      | 3   | .003*   | 14      | 14  | .003*   |
| Histological grade Low grade | 56 | 54 | 2 | .003* | 52 | 4   | 25    | 31    | 51 | 5 | .005* |
|           | High grade | 284 | 228 | 56 | .003* | 213   | 71   | 232   | 52   | 209 | 75 |
| Vascular invasion Absent | 234 | 205 | 50 | .001* | 203 | 31 | <.001* | 165 | 69 | .046* | 191     | 43  | .001*   |
|           | Present | 106    | 67     | 39   | .003*  | 62      | 44   | .003*  | 92      | 14  | .003*   | 69      | 37  | .003*   |
| Perineural invasion Absent | 321 | 271 | 50 | .003* | 259 | 62 | <.001* | 239 | 82 | .46*  | 253     | 68  | <.001*   |
|           | Present | 19     | 11     | 8    |         | 6       | 13   |         | 18      | 1   |         | 7       | 12  |         |
| Mitotic rate (per 10 high power fields) | 340 | 12.2 | 12.7 | .474 | 11.9 | 13.7 | .090 | 12.8 | 10.9 | .013* | 12.0 | 10.4+/-9.48 | .010* |
| CEBPD gene amplification Non-amp | 264 | 256 | 8 | .001* | 253 | 11 | <.001* | 184 | 80 | <.001* | 239     | 25  | <.001*   |
|           | Amp | 76      | 26     | 50   | .001*  | 12      | 64   | <.001*  | 73      | 3   | .047*   | 21      | 55  |         |
| CEBPD expression Low expression | 251 | 243 | 8 | <.001* | 239 | 12 | <.001* | 170 | 81 | <.001* | 240     | 11  | <.001*   |
|           | High expression | 89 | 39 | 50 | <.001* | 26 | 63 | - | 87 | 2 | 20 | 69 |
| MYC amplification Non-amp | 282 | 258 | 24 | <.001* | 203 | 79 | <.001* | 245 | 37 | <.001* |
|           | Amp | 58      | 7      | 51   | .001*  | 54      | 4    | .001*  | 15      | 43  |         | 15      | 43  |         |
| MYC expression Low expression | 265 | 187 | 78 | <.001* | 187 | 78 | <.001* | 238 | 27 | <.001* |
|           | High expression | 75 | 70 | 5 | <.001* | 70 | 5 | 22 | 53 |
| miR-429 expression Low expression | 257 | 188 | 69 | .011* | 188 | 69 | .011* | 72 | 11 |

*Chi-square test.
†Mann-Whitney U test.
*Statistical significance. Tumour samples were taken from the biobank of Chi Mei Medical Center.
the probable regulatory relationship between CEBPD and hsa-miR-429, which was predicted to regulate HK2 expression, was further examined. An in vitro experiment revealed that CEBPD overexpression inhibits the expression and promoter activity of hsa-miR-429 in BFTC909 and TCCSUP cells (Figure 4F,G). ChIP assays showed that endogenous CEBPD was recruited to the putative CEBPD binding site at the hsa-miR-429 promoter region in both cell types (Figure 4H). In addition, HK2 transcript was notably diminished after treatment with the hsa-miR-429 mimic but was upregulated after transfection with the hsa-miR-429 inhibitor in BFTC909 and TCCSUP cells (Figure 4I).

To clarify whether hsa-miR-429 inhibits the mRNA expression of HK2 by directly binding to its 3′-UTR, we cotransfected BFTC909 and TCCSUP cells with a miRNA negative control or an hsa-miR-429 mimic and WT- or mutant-HK2 3′-UTR firefly luciferase reporter (Figure 4B). Compared with the miRNA negative control, the hsa-miR-429 mimic robustly abolished the luciferase activity of the WT-HK2 3′-UTR in BFTC909 and TCCSUP cells, yet neither the miRNA negative control nor the hsa-miR-429 mimic induced the loss of mutant-HK2 3′-UTR luciferase activity (Figure 4J). Furthermore, CEBPD upregulated the mRNA level of HK2 upon transfection with the miRNA negative control but failed to robustly induce HK2 transcript expression after transfection of BFTC909 and TCCSUP cells with the hsa-miR-429 mimic (Figure 4K). These data suggest that CEBPD protects against the degradation of the HK2 transcript through the directly transcriptional suppression of hsa-miR-429.

3.4 High expression levels of MYC, CEBPD and HK2 are significantly associated with low hsa-miR-429 expression levels, and these expression patterns predict poor outcomes in UBUC and UTUC patients

With a solid validation in our well-characterized cohorts comprised of 295 UBUC patients and 340 UTUC patients as mentioned earlier, the present study disclosed MYC amplification, high MYC expression, high HK2 expression and low hsa-miR-429 expression were correlated with high pathological tumour (pT) stage, nodal metastasis, high histological grade, vascular and perineural invasion, a high mitotic rate and amplification/high expression of CEBPD. Moreover, MYC and CEBPD amplification and high expression and high HK2 expression showed significant positive correlations with each other but were negatively correlated with hsa-miR-429 expression (Tables 1 and 2, Figure 5A and Figure S8) (certain cases exhibited discordant MYC amplification and expression status). To explore the survival impacts of important clinicopathologic parameters and selected biomarkers, survival analysis was conducted at univariate and multivariate levels. In the univariate survival analysis, high pT stage; nodal metastasis; high histological grade; vascular invasion; perineural invasion; high mitotic rates; amplification of CEBPD or MYC; high expression of CEBPD, MYC, or HK2; low hsa-miR-429 expression and multifocality in UBUC and UTUC predicted poor DSS and MeFS (Figure 5B,2,4,5 and C1,2,4,5; Tables 3 and 4). Additionally, when considering the status of both the CEBPD and MYC transcription in BFTC909 and TCCSUP cells. Exogenous CEBPD overexpression significantly inhibited the expression (F) and promoter transactivity (G) of hsa-miR-429 through quantitative RT-PCR and luciferase reporter assays, respectively, in BFTC909 and TCCSUP cells. (H) Chromatin immunoprecipitation (ChIP) indicated that CEBPD is evidently recruited to the hsa-miR-429 promoter region in BFTC909 and TCCSUP cells, confirming the direct binding and transcriptional regulation of CEBPD on hsa-miR-429. (I) Interestingly, the transcription of HK2 was robustly diminished by treatment with the miR-429 mimic but promoted after treatment with the hsa-miR-429 inhibitor in BFTC909 and TCCSUP cells. Moreover, miR-429 mimic treatment significantly inhibited the relative luciferase activity of BFTC909 and TCCSUP cells transfected with pMIR-WT-HK2-3′-UTR-Luc but not pMIR-mutant-HK2-3′-UTR-Luc (J). (K) The transcription of HK2 was increased in CEBPD-overexpressing BFTC909 and TCCSUP cells compared to mock-expressing cells. However, compared with the vehicle, the miR-429 mimic robustly inhibited the increase in HK2 transcripts in CEBPD-overexpressing BFTC909 and TCCSUP cells. The aforementioned evidence revealed that CEBPD promotes HK2 expression through the transcriptional suppression of hsa-miR-429. All experiments were performed in triplicate and the results were represented as the mean ± SEM. For immunoblot assay, one representative image was displayed. GAPDH was shown as a loading control for immunoblot assay. Statistical significance: **p < .05
High expression of MYC, CCAAT/enhancer-binding protein delta (CEBPD) and HK2 along with low FBXW7 and hsa-miR-429 expression predicts adverse features and poor patient outcomes in urinary bladder urothelial carcinoma (UBUC) and upper urinary tract urothelial cancer (UTUC). (A) IHC and in situ hybridization showed that MYC amplification; high expression of MYC, CEBPD, and HK2; and low expression of FBXW7 and hsa-miR-429 were strongly relevant to UBUC patients (n = 295) with high tumour stage. (B–C) Moreover, Kaplan-Meier survival analysis indicated that both MYC amplification and high MYC expression are significant survival determinants in UBUC (n = 295; B1 and B2) and UTUC (n = 340; C1 and C2), while the survival impacts of MYC expression can be further enriched by the coexpression of CEBPD. (B3 and B4), suggesting potential synergistic effects of MYC and CEBPD in the promotion of UC progression. In addition, low expression of miR-429 and high expression of HK2 also confer a poor prognosis in terms of disease-specific survival in UBUC (n = 295; B4 and B5) and UTUC (n = 340; C4 and C5) patients. The UBUC and UTUC cohorts were taken from the biobank of Chi Mei Medical Center that collected specimens after an operation with curative intent between January 1996 and May 2004 as previously described. This study was approved by the institutional review board of Chi Mei Medical Center (IRB10207-001). For immunohistochemistry, one representative image was shown upper urinary tract urothelial cancer (UTUC).
| Parameter                | Category      | Case No. | Disease-specific survival | Univariate analysis | Multivariate analysis | Metastasis-free survival | Univariate analysis | Multivariate analysis |
|--------------------------|---------------|----------|---------------------------|---------------------|-----------------------|--------------------------|---------------------|-----------------------|
|                          |               |          | No. of events | p-value | RR  | 95% CI | p-value | No. of events | p-value | RR  | 95% CI | p-value |
| Sex                      | Male          | 216      | 41              | .4906    | -   | -      | -       | 61          | .2745   | -   | -      | -       |
|                          | Female        | 79       | 11              | -        | -   | -      | -       | 16          | -       | -   | -      | -       |
| Age (years)              | <65           | 121      | 17              | .1315    | -   | -      | -       | 32          | .8786   | -   | -      | -       |
|                          | ≥65           | 174      | 35              | -        | -   | -      | -       | 45          | -       | -   | -      | -       |
| Diabetes mellitus        | Negative      | 240      | 39              | .0547    | -   | -      | -       | 59          | .0638   | -   | -      | -       |
|                          | Positive      | 55       | 13              | -        | -   | -      | -       | 18          | -       | -   | -      | -       |
| Primary tumor (T)        | Ta            | 84       | 1               | < .0001* | 1   | -      | .001*   | 4           | < .0001* | 1   | -      | .010*   |
|                          | T1            | 88       | 9               | 4.276    | 0.448–40.851 |  -        | 23          | 3.543     | 1.021–12.295 | -   | -      | -       |
|                          | T2–T4         | 123      | 42              | 15.956   | 1.673–152.217 | -        | 50          | 5.391     | 1.493–19.466 | -   | -      | -       |
| Nodal metastasis         | Negative (N0) | 266      | 41              | .0001*   | 1   | -      | 0.733   | 61          | < .0001* | 1   | -      | .072    |
|                          | Positive (N1–N2) | 29     | 11              | 1.134    | 0.551–2.332 | -        | 16          | 1.756     | 0.951–3.243 | -   | -      | -       |
| Histological grade       | Low grade     | 56       | 2               | .0016*   | 1   | -      | 0.973   | 5           | .0007*   | 1   | -      | .785    |
|                          | High grade    | 239      | 50              | 0.972    | 0.190–4.982 | -        | 72          | 1.158     | 0.404–3.326 | -   | -      | -       |
| Vascular invasion        | Absent        | 246      | 37              | .0010*   | 1   | -      | 0.148   | 54          | < .0001* | 1   | -      | .895    |
|                          | Present       | 49       | 15              | 0.597    | 0.297–1.200  |  -        | 23          | 0.962     | 0.537–1.721 | -   | -      | -       |
| Perineural invasion      | Absent        | 275      | 44              | < .0001* | 1   | -      | 0.933   | 67          | .0003*   | 1   | -      | .155    |
|                          | Present       | 20       | 8               | 2.117    | 0.881–5.085  | -        | 10          | 1.748     | 0.809–3.774 | -   | -      | -       |
| Mitotic rate (per 10 high power fields) | <10         | 139      | 12              | < .0001* | 1   | -      | .031*   | 23         | < .0002* | 1   | -      | .050*   |
|                          | ≥10           | 156      | 40              | 2.110    | 1.071–4.156  | -        | 54          | 1.660     | 1.000–2.757 | -   | -      | -       |
| CEBPD amplification      | Nonamplified  | 232      | 30              | < .0001* | 1   | -      | -       | 42         | < .0001* | 1   | -      | -       |
|                          | Amplified     | 63       | 22              | -        | -   | -      | -       | 35          | -       | -   | -      | -       |
| CEBPD expression         | Low           | 207      | 22              | < .0001* | 1   | -      | 0.430   | 32          | < .0001* | 1   | -      | .003*   |
|                          | High          | 88       | 30              | 1.475    | 0.561–3.877 |  45      | 2.971     | 1.453–6.075 |  -   | -      | -       |
| MYC amplification        | Low           | 232      | 30              | < .0001* | 1   | -      | -       | 47         | < .0001* | 1   | -      | -       |
|                          | High          | 63       | 22              | -        | -   | -      | -       | 30          | -       | -   | -      | -       |
| MYC expression           | Low           | 210      | 19              | < .0001* | 1   | -      | 0.333   | 34         | < .0001* | 1   | -      | .495    |
|                          | High          | 85       | 33              | 1.518    | 0.653–3.531 |  43      | 1.259     | 0.650–2.439 | -   | -      | -       |
| miR-429 expression       | Low           | 194      | 48              | < .0001* | 1   | -      | 0.352   | 66         | < .0001* | 1   | -      | .437    |
|                          | High          | 101      | 4               | 0.584    | 0.188–1.813 |  11      | 0.751     | 0.364–1.547 | -   | -      | -       |
| HK2 expression           | Low           | 225      | 27              | < .0001* | 1   | -      | 0.728   | 46         | < .0001* | 1   | -      | .180    |
|                          | High          | 70       | 25              | 1.150    | 0.523–2.531 |  31      | 0.660     | 0.359–1.212 | -   | -      | -       |

*Statistical significance.
| Parameter                  | Category     | Case No. | No. of events | p-value | Univariate analysis | RR  | 95% CI | p-value | Multivariate analysis | RR  | 95% CI | p-value |
|----------------------------|--------------|----------|---------------|---------|---------------------|-----|--------|---------|-----------------------|-----|--------|---------|
| Sex                        | Male         | 158      | 28            | .9301   | –                   | –   | –      | –       | –                     | –   | –      | –       |
|                            | Female       | 182      | 33            | –       | –                   | –   | –      | –       | 38                    | –   | –      | –       |
| Age (years)                | < 65         | 138      | 26            | .8660   | –                   | –   | –      | –       | 30                    | .8470 | –      | –       |
|                            | ≥ 65         | 202      | 35            | –       | –                   | –   | –      | –       | 40                    | –   | –      | –       |
| Diabetes mellitus          | Negative     | 276      | 45            | .0867   | –                   | –   | –      | –       | 52                    | .928  | –      | –       |
|                            | Positive     | 64       | 16            | –       | –                   | –   | –      | –       | 18                    | –   | –      | –       |
| Multifocality              | Single       | 273      | 43            | .0042 * | 1                   | –   | –      | .003 * | 52                    | .0196 | 1      | –       |
|                            | Multifocal   | 62       | 18            | 2.474   | 1.361–4.495         | .003 * | 1      | –       | 18                    | 2.075 | 1.175–3.665 | –       |
| Primary tumor (T)          | Ta           | 89       | 2             | <.0001 * | 1                   | –   | –      | .035 * | 4                     | <.0001 * | 1      | –       |
|                            | T1           | 92       | 9             | 2.976   | 0.598–14.808        | .0042 * | 1      | –       | 15                    | 2.536 | 0.779–8.254 | –       |
|                            | T2–T4        | 159      | 50            | 4.993   | 1.082–23.040        | .260  | <.0001 * | 1      | 51                    | 3.322 | 1.006–10.976 | –       |
| Nodal metastasis           | Negative (N0)| 312      | 42            | <.0001 * | 1                   | –   | –      | <.001 * | 55                    | <.0001 * | 1      | –       |
|                            | Positive (N1–N2)| 28     | 19            | 3.211   | 1.666–6.191         | .045  | 1      | –       | 15                    | 1.446 | 0.761–2.744 | –       |
| Histological grade         | Low grade    | 56       | 4             | .0171 * | 1                   | –   | –      | .045 * | 3                     | .0019 * | 1      | –       |
| Vascular invasion          | Absent       | 234      | 24            | <.0001 * | 1                   | –   | –      | .104 * | 26                    | <.0001 * | 1      | –       |
|                            | Present      | 106      | 37            | 1.653   | 0.902–3.030         | .0019 * | 1      | –       | 44                    | 2.787 | 1.516–5.125 | –       |
| Perineural invasion        | Absent       | 321      | 50            | <.0001 * | 1                   | –   | –      | .003 * | 61                    | <.0001 * | 1      | –       |
|                            | Present      | 19       | 11            | 3.208   | 1.475–6.978         | .109  | 1      | –       | 9                     | 1.897 | 0.867–4.152 | –       |
| Mitotic rate (per 10 high power fields) | < 10   | 173      | 27            | .1268   | –                   | –   | –      | –       | 30                    | .0581 | –      | –       |
|                            | ≥ 10         | 167      | 34            | –       | –                   | –   | –      | –       | 40                    | –   | –      | –       |
| CEBPD Amplification        | Nonamplified | 264      | 29            | <.0001 * | 1                   | –   | –      | –       | 24                    | <.0001 * | 1      | –       |
|                            | Amplified    | 76       | 32            | –       | –                   | –   | –      | –       | 46                    | –   | –      | –       |
| CEBPD expression           | Low          | 251      | 26            | <.0001 * | 1                   | –   | –      | .212 * | 24                    | <.0001 * | 1      | –       |
|                            | High         | 89       | 35            | 1.758   | 0.725–4.260         | .004 * | 1      | –       | 46                    | 3.506 | 1.484–8.282 | –       |
| MYC amplification          | Low          | 282      | 33            | <.0001 * | 1                   | –   | –      | –       | 35                    | <.0001 * | 1      | –       |
|                            | High         | 58       | 28            | –       | –                   | –   | –      | –       | 35                    | –   | –      | –       |
| MYC expression             | Low          | 265      | 23            | <.0001 * | 1                   | –   | –      | .013 * | 27                    | <.0001 * | 1      | –       |
|                            | High         | 75       | 38            | 2.651   | 1.228–5.723         | .013 * | 1      | –       | 43                    | 2.478 | 1.214–5.059 | –       |
| miR-429 expression         | Low          | 257      | 55            | .0024 * | 1                   | –   | –      | .966 * | 64                    | <.0001 * | 1      | –       |
|                            | High         | 83       | 6             | 0.997   | 0.386–2.579         | .948  | 1      | –       | 6                     | 0.970 | 0.392–2.401 | –       |
| HK2 expression             | Low          | 260      | 35            | <.0001 * | 1                   | –   | –      | .142 * | 34                    | <.0001 * | 1      | –       |
|                            | High         | 80       | 26            | 0.580   | 0.280–1.200         | .277  | 1      | –       | 36                    | 0.688 | 0.351–1.350 | –       |

*Statistical significance.
expression, the presence of both high MYC expression and high CEBPD expression indicated a more aggressive clinical course (Figure 5B3 and C3, Tables 3 and 4). In the multivariate analysis, UBUC patients with a high pT stage and a high mitotic rate and UTUC patients with multifocality and high MYC expression displayed worse DSS and MeFS than other patients (Tables 3 and 4). These data manifested that a high level of MYC, CEBPD, HK2 and low expression of hsa-miR429 were frequently observed in aggressive UC with unfavourable survival outcomes. Especially, the combination of high expression of MYC and CEBPD represented the worst outcomes in patients with UBUC and UTUC.

### 3.5 CEBPD upregulation synergizes with glucose metabolism disorder to promote UC progression

Given that the aforementioned evidence revealed that positive feedback loops between CEBPD and MYC drive metabolic reprogramming toward glycolysis, we further evaluated whether DM, the most common cause of dysregulated glucose homeostasis and high glucose levels in peripheral tissue, is associated with a poor outcome among UC patients in nationwide cohorts. We confirmed the prognostic significance of glucose metabolism disorder in 8436 UBUC patients and 3232 UTUC patients from the NHIRD. DM patients had higher 5- and 10-year mortality rates than non-DM patients, with hazard ratios of 1.22 (5-year survival for UBUC patients; 95% CI: 1.14–1.30, p < .001), 1.12 (5-year survival for UTUC patients; 95% CI: 1.01–1.26, p = .044), 1.29 (10-year survival for UBUC patients; 95% CI: 1.22–1.37, p < .001) and 1.17 (10-year survival for UTUC patients; 95% CI: 1.06–1.29, p = .003), after adjusting for all comorbidities (Tables 7 and 8, Figure 6A1,5). Interestingly, the mortality risks of age, sex and comorbidities except COPD were irrelevant to the impact of DM status on UBUC and UTUC patients (Table S9), reinforcing DM as an independent prognostic factor in UC.

We then further explored whether DM is a survival determinant in UC and enhances CEBPD-driven progression in our in-house cohorts as well as a xenograft model. We found that the prognostic significance of concomitant DM only reached marginal significance in the prediction of inferior DSS in UBUC (p = .0547) and UTUC (p = .0867) in our cohort (Figure 6A2,6); the significance was probably less pronounced because our study included far fewer cases than the NHIRD. Nevertheless, concomitant DM was a significant predictor of worse outcomes in patients with high tumoral CEBPD expression (UBUC p = .0046; UTUC p = .0187) (Figure 6A3,7), and vice versa (UBUC p = .0001; UTUC p < .0001) (Figure 6A4,8).

Aside from clinical significance, deterioration of CEBPD-driven tumour aggressiveness was also examined in an animal model with induced type 2 DM. In BFTC909-xenografted SCID/beige mice without induced DM, the tumour size of the CEBPD-overexpressing group was larger than that of the mock group (Figure 6B). Interestingly, the tumour growth advantage conferred by CEBPD overexpression was even more exacerbated in mice with high-fat-diet-induced DM than in those with mock cell-derived xenografts with or without DM and in those with CEBPD-overexpressing cell-derived xenografts without DM (Figure 6B). The tumour growth advantage was also supported by the upregulation of pAKT1, pMTOR, pRPS6, pEIF4EBP1, MKI67, MYC and HK2 and the downregulation of hsa-miR-429 (Figure 6C and Figure S9). Based on the above data, we disclosed DM is synergistically unfavourable to the survival outcome among patients with high expression of CEBPD by means of the aggressive tumour growth stemmed from the metabolic disorder of mTOR signalling and glycolysis.

### 4 DISCUSSION

In the present study, we consolidated the oncogenic features of CEBPD on UC through MAPK- and PI3K/AKT-dependent mTORC1 axis which is the pivotal hub for cell growth. Furthermore, we noticed that CEBPD amplification is frequently accompanied by the amplification of MYC—the ‘master regulator’ of glycolysis in our aCGH cohort. Accordingly, this co-amplification confers more clinical aggressiveness which warrants further exploration of its biological significance. Moreover, we confirmed that CEBPD has a novel carcinogenic ability to impose metabolic reprogramming, facilitating the switch from mitochondrial OXPHOS to glycolysis, resulting in glucose addiction on UC. CEBPD-induced high glucose demand was verified in SCID/beige mice with high-fat-diet-induced DM. CEBPD accelerated tumour growth more potently in mice with DM than in those without DM. The findings mentioned above were further supported by significant correlations in our large clinical cohort and cohorts from the NHIRD. This CEBPD and MYC-centric multilayered positive feedback loop enhances oncogenic glycolysis, which ensures cancer growth, especially during glucose metabolism dysregulation, indicating that it could be a target for combined treatment strategies. Albeit we clearly demonstrated the positive interplay of CEBPD and MYC on neoplastic progression, it is still worthwhile to excavate the potential oncogenic significance of CEBPD through the MAPK- and PI3K/AKT-dependent mTORC1 survival signalling.
Clinically aggressive features are correlated with genetic alterations, especially copy number aberration in solid tumours, including UC.\textsuperscript{21} CIN distinguishes invasive UC from less aggressive papillary subtypes.\textsuperscript{42} We previously identified the frequent amplification of chromosomes 3q, 5p, 8q and 19q, as well as copy number losses of 2q, 4q, 5q, 6q, 9p, 9q, 11p, 11q, 13p 17p and 18q in muscle-invasive UBUC.\textsuperscript{23} Of these changes, the CNG of chromosome 8q is highly recurrent in aggressive UC. Importantly, 8q24 manifests as the most dominant amplification core during UC progression\textsuperscript{43} and is one of the most significant copy number imbalances associated with metastasis development and a poor prognosis in UBUC.\textsuperscript{10} Amplification of MYC mapped to chromosome 8q24.21 is commonly observed in aggressive types of cancers and is strikingly related to a high risk of relapse and disease-related death.\textsuperscript{44} MYC dysregulation induces genome instability such as CIN\textsuperscript{18,45} may explain why MYC amplification is strongly linked to copy number aberrations of other oncogenes, such as HER2 amplification in 40% of breast cancer and 5% of gastric cancer cases.\textsuperscript{19,46} HER2 was also detected to be coamplified with MYC (\(p < .01\)) in UC. The coamplification of HER2 and MYC was also detected in 6% of UCs that were all in late-stage.\textsuperscript{47} Moreover, overexpression of MYC has been reported to drive the amplification of DHFR, a critical enzyme in de novo purine and thymidylate biosynthesis, in human cell lines and preinvasive cervical cancer.\textsuperscript{20,48}

The current study is the first not only to reveal MYC expression induces an increased LOH in vitro as solid evidence of MYC-induced CIN but also a positive correlation between the MYC and CEBPD gene dosages and expression levels in vitro and in vivo. Interestingly, an in vitro experiment showed that MYC overexpression induced CEBPD amplification but not vice versa. Moreover, CEBPD amplification was exclusively identified in patients with MYC gain, while the reverse pattern was not observed. These lines of evidence strongly support the hypothesis that MYC gain develops earlier than CEBPD gain and that MYC expression drives amplification-driven CEBPD expression in UC. This is also supported by the fact that MYC amplification is more frequent than CEBPD amplification in UC and can even be observed in preinvasive high-grade dysplasia, while CEBPD gain is less frequently found and is preferentially observed in an aggressive subset of UCs.\textsuperscript{10,49}

An earlier study reported that MYC overexpression in UC does not necessarily depend on its amplification\textsuperscript{50} and that the frequency of MYC overexpression surpasses that of MYC amplification in some tumour types, such as gastric adenocarcinoma.\textsuperscript{51} Similarly, a broad analysis of the TCGA database, which contains approximately 9000 specimens comprising 33 tumour types, showed that colon adenocarcinoma and rectum adenocarcinoma exhibit the highest MYC mRNA levels, but this upregulation is attributed to Wnt/\(\beta\)-catenin signalling pathway activity instead of MYC amplification; chromophobe renal cell carcinoma (KICH) exhibits the highest MYC protein expression level but has a low MYC mRNA level and a low frequency of MYC amplification, suggesting that mRNA stability and translational or posttranslational regulation play roles in MYC protein expression levels.\textsuperscript{52} Similarly, MYCN (MYC protooncogene, bHLH transcription factor) is amplified in approximately 20% of neuroblastomas

\textbf{FIGURE 6} Diabetes mellitus (DM) exacerbates CCAAT/enhancer-binding protein delta (CEBPD)-driven tumour aggressiveness. (A) Analysis of the National Health Insurance Research Database (NHIRD) showed that urinary bladder urothelial carcinoma (UBUC) (A1, \(n = 8436, p < .001\)) and upper urinary tract urothelial cancer (UTUC) (A5, \(n = 3232, p = .003\)) patients with concomitant DM had a higher death rate than non-DM patients. However, unlike the results for the NHIRD, which includes a large number of patients, concomitant DM only displayed marginal significance for the prediction of poor disease-specific survival (DSS) in UBUC (A2, \(n = 295, p = .0547\)) and UTUC (A6, \(n = 340, p = .0867\)) in our cohort, which includes few cases, indicating that the significance of DM in patients' outcome might be mild. Interestingly, for those cases with high CEBPD expression in our cohort, the presence of DM conferred a significantly worse prognosis in UBUC (A3, \(n = 88, p = .0046\)) and UTUC (A7, \(n = 89, p = .0187\)). Conversely, tumours harbouring high CEBPD expression were even more aggressive in DM patients in both the UBUC (A4, \(n = 55, p = .0001\)) and UTUC (A8, \(n = 64, p < .0001\)) cohorts. The aforementioned evidence revealed that CEBPD-mediated aggressiveness in UC can be exacerbated by concomitant hyperglycemic disorder, a symptom that characterizes diabetes, probably because high-glucose conditions help to reinforce CEBPD-mediated glycolysis in cancer cells. (B) Experiments on a BFTC909-derived xenograft model (\(n = 8\) for each group) further reinforced that the effects of CEBPD on promoting tumour growth could be exacerbated by concomitant hyperglycemia. First, compared with the mock conditions, CEBPD overexpression promoted the growth of xenografted tumours in SCID/beige mice without high-fat diet-induced DM. Accelerated tumour growth driven by CEBPD overexpression was exacerbated in mice with high-fat-diet-induced DM compared with those with CEBPD overexpression alone or induced DM alone (B1). The CEBPD-induced and DM-induced effects on tumour aggressiveness and the DM-induced exacerbation of CEBPD-driven tumour growth were all statistically significant (B2). (C) IHC analysis of xenografted samples at day 25 post-injection showed that pAKT1, pMTOR, pPRPS6, pEIF4EBP, MKI67, MYC and HK2 were highly expressed and that hsa-miR-429 were downregulated in the CEBPD-overexpressing and/or DM-induced groups compared to the control group. Of note, the upregulation of MYC and HK2 and downregulation of hsa-miR-429 were more prominent in the CEBPD-overexpressing group than in the mock group, regardless of DM induction. This suggests that the CEBPD-mediated effects on glycolysis might be regardless of hyperglycemia or normoglycemia conditions. For immunohistochemistry, one representative image was shown. Data are shown as the mean ± SEM. Statistical significance: *\(p < .05\)
(NBs) and is related to poor outcomes.\textsuperscript{53} Nevertheless, most NB tumours have substantial nuclear MYCN protein expression and relatively low MYCN mRNA levels, implying an alternative route for the protein stabilization of MYCN in this type of tumour.\textsuperscript{54} MYC and many other oncogenes, such as CCNE1, MTOR, JUN, NOTCH1 and AURKA, are targeted for ubiquitin-proteasome-mediated destruction by the vital tumour suppressor FBXW7, a component of the SCF E3 ligase complex.\textsuperscript{39} FBXW7 dysregulation is one means of tumorigenesis in various cancer types. Loss of function and low transcription of FBXW7 indicate unfavourable survival outcomes and are related to the aggression of muscle-invasive BLCA due to MYC accumulation.\textsuperscript{55} CEBPD has been implicated in MTOR signalling enhancement by transcriptionally suppressing FBXW7, leading to mammary tumour metastasis.\textsuperscript{56} Our current study is the first to reveal that CEBPD exerts a protective effect by stabilizing MYC by transcriptionally repressing FBXW7 in UC. Although this study did not reveal a novel MYC regulatory mechanism, our results could explain why the MYC protein and mRNA expression patterns are often inconsistent in many cancers.

Dysregulated PI3K/AKT/mTOR pathway is one of the most important oncogenic signalings. In the present study, we also found that CEBPD activates the MAPK3/1 (ERK1/2) and PI3K/AKT/mTORC1 pathways in UC cell lines. MAPK3/1 (ERK1/2) plays a key role in tumour growth by regulating cell cycle progression.\textsuperscript{57} mTOR is a serine-threonine kinase that forms two multiprotein complexes, namely, mTORC1 and mTORC2.\textsuperscript{38} Both mTORC1 and mTORC2 induce metabolic reprogramming by enforcing protein and lipid synthesis, aerobic glycolysis, and mitochondrial modulation to fuel tumour progression.\textsuperscript{59,60} Of these pathways, aerobic glycolysis is a cancer hallmark for rapid energy production in the presence of oxygen to promote cell growth.\textsuperscript{22,61,62} mTORC1 promotes aerobic glycolysis by promoting the transcription of glycolysis-related enzymes, including HK2, LDH A/C, pyruvate dehydrogenase kinase and glucose transporters, via hypoxia-inducible factor 1 (HIF-1) and MYC.\textsuperscript{63} mTORC2 governs glycolytic metabolism mainly through MYC and AKT.\textsuperscript{63} Apparently, dual regulation of MYC by the AKT/mTORC1 axis and mTORC2 has profound implications for glycolysis. The present study revealed that aerobic glycolysis is enhanced by CEBPD in UC cells by increased glucose uptake following increases in GLUT-1 and HK2. Of note, we identified CEBPD promotes mitochondrial fission, which favours glycolysis over OXPHOS, supports the increase in ECAR and decrease in OCR in CEBPD-overexpressing UC cells, reenforcing the glycolytic shift induced by CEBPD. Moreover, CEBPD strengthens glycolytic flux at least partly through MYC regulation, as verified by the partial loss in GLUT-1 and HK2 expression after siMYC treatment in CEBPD-overexpressing cells. For the first time, our findings disclosed a novel insight regarding oncogenic characters of CEBPD as an enhancer of glycolysis.

HK2 belongs to the hexokinase family, which is composed of four isoforms (HK1, HK2, HK3 and HK4).\textsuperscript{64} HK2 is a crucial glycolytic enzyme that converts glucose to G6P in the first step of glycolysis\textsuperscript{64} and functions as an oncogene. It has been found to be highly upregulated in cancers and to be associated with poor clinical outcomes.\textsuperscript{65,66} Numerous miRNAs have been found to regulate various metabolic pathways directly by targeting these key enzymes or indirectly by impacting the levels of transcription factors.\textsuperscript{67} Interestingly, various miRNAs participate in glycolytic reprogramming by targeting glucose transporters and glycolytic enzymes in tumours.\textsuperscript{68} However, few previous reports have revealed the role of miRNAs in the regulation of HK2 expression in UC. To date, only hsa-miR-125b-5p has been reported to directly target HK2 to suppress the progression of BLCA.\textsuperscript{69} Our report expanded the spectrum of miRNAs that regulate glycolysis in UC by highlighting the role of miR-429, where direct transcriptional repression of hsa-miR-429 by CEBPD promotes HK2 expression. miR-429 belongs to the miR-200 family (i.e., miR-200a, miR-200b, miR-200c, miR-141 and miR-429) and functions as a tumour suppressor, tumour promoter or both depending on the tumour type and expression pattern.\textsuperscript{70} miR-429 has previously been shown to have a role in BLCA by suppressing the migration and invasion of a BLCA cell line by targeting zinc finger E-box binding homeobox 1 and β-catenin, both of which are related to epithelial-mesenchymal transition.\textsuperscript{71} A computational algorithm further revealed an additional role of miR-429 as a potential negative modulator of anaerobic glycolysis by affecting the gene level of HIF-1α.\textsuperscript{67} Finally, miR-429 may serve as a prospective biomarker of clinicopathological traits and prognostic outcomes.\textsuperscript{72} We expanded these known roles in the present study, where we revealed that miR-429 plays a crucial role in the CEBPD-induced promotion of glycolysis.

In conclusion, we unearthed that the CIN of MYC drives CEBPD amplification and that the upregulation of CEBPD plays a protective role by stabilizing the MYC protein through the transcriptional suppression of FBXW7 in UC-derived cell lines. Cell proliferation, glucose addiction, and switching from mitochondrial fusion to fission are promoted as a result of mTOR signalling hyperactivation and MYC-dependent glycolysis dysregulation induced by CEBPD overexpression. CEBPD also promotes glycolysis by inhibiting hsa-miR-429, thus upregulating HK2 in an MYC-independent manner. Overall, we are the first to show that glycolysis is promoted via the CEBPD/FBXW7/MYC positive feedback loop and the
novel CEBPD/hsa-miR-429/HK2 axis. Taken together, our data indicate a novel role of CEBPD in metabolic reprogramming. More importantly, given that directly targeting MYC has been proved difficult, our study disclosed a possible combined treatment strategy targeting both MYC and CEBPD to more effectively prohibit MYC-initiated tumorigenesis.

ACKNOWLEDGEMENTS
The authors thank Dr Tzu-Ju Chen and Dr Wan-Shan Li (Chi Mei Medical Center, Tainan, Taiwan) for their assistance with the pathological examination of tissue specimens and the BioBank of Chi Mei Medical Center. We thank Dr Mei-Yeh Lu and the High Throughput Sequencing Core hosted in the Biodiversity Research Center at Academia Sinica for performing the NGS experiments. The core facility is funded by Academia Sinica Core Facility and Innovative Instrument Project (AS-CFII-108-114). We are also grateful to Chia-Chun Chiu (Genetics Generation Advancement Corp) and Yen-Liang Lee (Welgene Biotech, Taiwan) for their kind support of the process and analysis of NGS experiments. We are also grateful to Dr Hsiang-Ying Lee for helping with the process of data analysis. This work was supported by grants from the Ministry of Science and Technology of Taiwan (109-2628-B-384-003, 109-2628-B-384-001) and in part by grants from the National Health Research Institutes of Taiwan (CA-110-PP-11) and Chi Mei Medical Center.

CONFLICT OF INTEREST
The authors declare that they have no conflict of interest.

ORCID
Ju-Ming Wang https://orcid.org/0000-0002-1094-860X
Chien-Feng Li https://orcid.org/0000-0002-9527-7576

REFERENCES
1. Leow JJ, Liu Z, Tan TW, Lee YM, Yeo EK, Chong Y-L. Optimal management of upper tract urothelial carcinoma: current perspectives. Onco Targets Ther. 2020;13:1-15.
2. Yang M-H, Chen K-K, Yen C-C, et al. Unusually high incidence of upper urinary tract urothelial carcinoma in Taiwan. Urology. 2002;59(5):681-687.
3. Letašiová S, Medve’ová A, Šovčíková A, et al. Bladder cancer, a review of the environmental risk factors. Environ Health. 2012;11(Suppl 1):S1-S11. http://doi.org/10.1186/1476-069X-11-S1-S11.
4. Abol-Enein H. Infection: is it a cause of bladder cancer? Scand J Urol Nephrol Suppl. 2008(218):79-84.
5. Soria F, Krabbe L-M, Todenhöfer T, et al. Molecular markers in bladder cancer. World J Urol. 2019;37(1):31-40.
6. Yao Y, Dai W. Genomic instability and cancer. J Carcinog Mutagen. 2014;5:1000165.
7. Felsher DW, Bishop JM. Transient excess of MYC activity can elicit genomic instability and tumorigenesis. Proc Natl Acad Sci. 1999;96(7):3940-3944.
8. Vargas-Rondón N, Villegas VE, Rondón-Lagos M. The Role of chromosomal instability in cancer and therapeutic responses. Cancers. 2017;10(1):4.
9. Florl AR, Schulz WA. Chromosomal instability in bladder cancer. Arch Toxicol. 2008;82(3):173-182.
10. Wang Y-H, Wu W-J, Wang W-J, et al. CEBPD amplification and overexpression in urothelial carcinoma: a driver of tumor metastasis indicating adverse prognosis. Oncotarget. 2015;6(31):31069-31084.
11. Balamurugan K, Sternecken E. The many faces of C/EBPδ and their relevance for inflammation and cancer. Int J Biol Sci. 2013;9(9):917-933.
12. Sowamber R, Chehade R, Bitar M, et al. CCAAT/enhancer binding protein delta (C/EBPδ) demonstrates a dichotomous role in tumour initiation and promotion of epithelial carcinoma. EBioMedicine. 2019;44:261-274.
13. Hartl I, Duitman J, Aberson HL, et al. CCAAT/enhancer-binding protein delta (C/EBPδ): a previously unrecognized tumor suppressor that limits the oncogenic potential of pancreatic ductal adenocarcinoma cells. Cancers. 2020;12(9):2546.
14. Wang S-M, Lin W-C, Lin H-Y, Chen Y-L, Ko C-Y, Wang J-M. CCAAT/enhancer-binding protein delta mediates glioma stem-like cell enrichment and ATP-binding cassette transporter ABCA1 activation for temozolomide resistance in glioblastoma. Cell Death Discov. 2021;7(1):8.
15. Chuang CH, Wang WJ, Li CF, et al. The combination of the prodrugs perforin-CEBD and perforin-granzyme B efficiently enhances the activation of caspase signaling and kills prostate cancer. Cell Death Dis. 2014;5(5):e1220-e1220.
16. Wahlström T, Arsenian Henriksson M. Impact of MYC in regulation of tumor cell metabolism. Biochimica et Biophysica Acta. 2015;1849(5):563-569.
17. Camarda R, Williams J, Goga A. In vivo reprogramming of cancer metabolism by MYC. Front Cell Dev Biol. 2017;5:35.
18. Kuzyk A, Mai S. c-MYC-induced genomic instability. Cold Spring Harb Perspect Med. 2014;4(4):a043735.
19. Park K, Kwak K, Kim J, Lim S, Han S. c-myc amplification is associated with HER2 amplification and closely linked with cell proliferation in tissue microarray of nonselected breast cancers. Hum Pathol. 2005;36(6):634-639.
20. Mai S, Hanley-Hyde J, Fluri M. c-Myc overexpression associated DHFR gene amplification in hamster, rat, mouse and human cell lines. Oncogene. 1996;12(2):277-288.
21. Lücke-Huhle C. Permissivity for methotrexate-induced DHFR gene amplification correlates with the metastatic potential of rat adenocarcinoma cells. Carcinogenesis. 1994;15(4):695-700.
22. Chan T-C, Wu W-J, Li W-M, Shiao M-S, Shiue Y-L, Li C-F. SLC14A1 prevents oncometabolite accumulation and recruits HDAC1 to transrepress oncometabolite genes in urothelial carcinoma. Theranostics. 2020;10(25):11775-11793.
23. Wu WR, Lin JT, Pan CT, et al. Amplification-driven BCL6-suppressed cytostasis is mediated by transpression of FOXO3 and post-translational modifications of FOXO3 in urinary bladder urothelial carcinoma. Theranostics. 2020;10(2):707-724.
24. Qiu X, Ma F, Zhao M, et al. Altered 3D chromatin structure permits inversional recombination at the IgHocus. Sci Adv. 2020;6(33):eaa28850.

25. Servant N, Varoquaux N, Lajoie BR, et al. HiC-Pro: an optimized and flexible pipeline for Hi-C data processing. Genome Biol. 2015;16:259.

26. Servant N, Lajoie BR, Nora EP, et al. HiTC: exploration of high-throughput ‘C’ experiments. Bioinformatics. 2012;28(21):2843-2844. Nov 1.

27. Bruin Jennifer E, Saber N, Braun N, et al. Treating diet-induced diabetes and obesity with human embryonic stem-derived pancreatic progenitor cells and antidiabetic drugs. Stem Cell Rep. 2015;4(4):605-620.

28. Wang Yu-Hui, Wu Wen-Jeng, Wang Wei-Jan, Huang Hsuan-Ying, Li Wei-Meng, Yeh Bi-Wen, Wu Ting-Feng, Shiue Yow-Ling, Sheu Jim Jinn-Chyuan, Wang Ju-Ming & Li Chien-Feng. CEBPD amplification and overexpression in urothelial carcinoma: a driver of tumor metastasis indicating adverse prognostic. Oncotarget. 2015;6(31):31069-31084. https://doi.org/10.18632/oncotarget.5209

29. Hua H, Kong Q, Zhang H, Wang J, Luo T, Jiang Y. Targeting mTOR for cancer therapy. J Hematol Oncol. 2019;12(1):71.

30. Yu X, Wang R, Zhang Y, et al. Skp2-mediated ubiquitination and mitochondrial localization of AKT drive tumor growth and chemoresistance to cisplatin. Oncogene. 2019;38(50):7457-7472.

31. Saxton RA, Sabatini DM. mTOR signaling in growth, metabolism, and disease. Cell. 2017;168(6):960-976.

32. Leprivier G, Rotblat B. How does mTOR sense glucose starvation? AMPK is the usual suspect. Cell Death Discov. 2016;6(1):27.

33. Ramirez-Perinado S, León-Annicchiarico CL, Galindo-Moreno J, et al. Glucose-starved cells do not engage in prosurvival autophagy. J Biol Chem. 2013;288(42):30387-30398.

34. Tanner LB, Goglia AG, Wei MH, et al. Four key steps control glycolytic flux in mammalian cells. Cell Syst. 2018;7(1):49-62.

35. Wolf A, Agnihotri S, Micallef J, et al. Hexokinase 2 is a key mediator of aerobic glycolysis and promotes tumor growth in human glioblastoma multiforme. J Exp Med. 2011;208(2):313-326.

36. Dang CV, Le A, Gao P. MYC-induced cancer cell energy metabolism and therapeutic opportunities. Clin Cancer Res. 2009;15(21):6479-6483.

37. Christoph F, Schmidt B, Schnitz-Dräger BJ, Schulz WA. Overexpression and amplification of the c-myc gene in human urothelial carcinoma. Int J Cancer. 1999;84(2):169-173.

38. Davis RJ, Welcker M, Clurman BE. Tumor suppression by the Fbw7 ubiquitin ligase: mechanisms and opportunities. Cancer Cell. 2014;26(4):455-464.

39. Yeh C-H, Bellon M, Nicot C. FBXW7: a critical tumor suppressor of human cancers. Mol Ther. 2018;17(1):115.

40. Sailo BL, Banik K, Girisa S, et al. FBXW7 in cancer: what has been unraveled thus far? Cancers. 2019;11(2):246.

41. Ormoft TF, Wolf H. Molecular alterations in bladder cancer. Urol Res. 1998;26(4):223-233.

42. Florl AR, Schulz WA. Chromosomal instability in bladder cancer. Arch Toxicol. 2008;82(3):173-182.

43. Watters AD, Latif Z, Forsyth A, et al. Genetic aberrations of c-myc and CCND1 in the development of invasive bladder cancer. Br J Cancer. 2002;87(6):654-658.

44. Kalkat M, De Melo J, Hickman KA, et al. MYC deregulation in primary human cancers. Genes. 2017;8(6):151.

45. Rohrberg J, Van de Mark D, Amouzgar M, et al. MYC regulates mitosis, revealing cancer vulnerabilities. Cell Rep. 2020;30(10):3368-3382.

46. Mitsuji F, Dobashi Y, Imoto I, et al. Non-incidental coamplification of MYC and ERBB2, and MYC and EGFR, in gastric adenocarcinomas. Mod Pathol. 2007;20(6):622-631.

47. Hansel DE, Swain E, Dreicer R, Tubbs RR. HER2 overexpression and amplification in urothelial carcinoma of the bladder is associated with MYC coamplification in a subset of cases. Am J Clin Pathol. 2008;130(2):274-281.

48. Gujjon FB, Greulich-Bode K, Paraskevas M, Baker P, Mai S. Premalignant cervical lesions are characterized by dihydrofolate reductase gene amplification and c-Myc overexpression: possible biomarkers. J Low Genit Tract Dis. 2007;11(4):265-272.

49. Sarbia M, Arjumand J, Wolter M, Reifenberger G, Heep H, Gabbert HE. Frequent c-myc amplification in high-grade dysplasia and adenocarcinoma in Barrett’s esophagus. Am J Clin Pathol. 2001;115(6):835-840.

50. Mahdy E, Pan Y, Wang N, Malmström PU, Ekman P, Berger-Heim U. Chromosome 8 numerical aberration and C-MYC copy number gain in bladder cancer are linked to stage and grade. Anticancer Res. 2001;21(5):3167-3173.

51. Khaleghian M, Jahanzad I, Shakoori A, Emami Razavi A, Azimi C. Association between amplification and expression of C-MYC gene and clinicopathological characteristics of stomach cancer. Iran Red Crescent Med J. 2016;18(2):e21221.

52. Schaub FX, Dhankani V, Berger AC, et al. Pan-cancer Alterations of the MYC oncogene and its proximal network across the cancer genome atlas. Cell Syst. 2018;6(3):282-300.

53. Berbegall AP, Bogen D, Pötschger U, et al. Heterogeneous MYCN amplification in neuroblastoma: a SIOP Europe Neuroblastoma Study. Br J Cancer. 2018;118(1):1502-1512.

54. Valentijn LJ, Koster J, Haneveld F, et al. Functional MYCN signature predicts outcome of neuroblastoma irrespective of MYCN amplification. Proc Nat Acad Sci. 2012;109(47):19190-19195.

55. Matumoto T, Chen Y, Contreras-Sanz A, et al. FBXW7 loss of function contributes to worse overall survival and is associated with accumulation of MYC in muscle invasive bladder cancer. Urol Oncol. 2020;38(12):904-905.

56. Balamurugan K, Wang J-M, Tsai H-H, et al. The tumour suppressor C/EBPδ inhibits FBXW7 expression and promotes mammary tumour metastasis. EMBO J. 2010;29(24):4106-4117.

57. Meloche S, Pouységur J. The ERK1/2 mitogen-activated protein kinase pathway as a master regulator of the G1-to-S-phase transition. Oncogene. 2007;26(22):3227-3239.

58. Lim JS, Chen Y, Roh JS, et al. The tumor suppressor C/EBPδ inhibits FBXW7 expression and contributes to prostate cancer progression. Oncogene. 2007;26(22):3227-3239.

59. Kim J, Guan K-L. mTOR as a central hub of nutrient signalling and cell growth. Nat Cell Biol. 2019;21(1):63-71.

60. Linke M, Fritsch SD, Sukhbaatar N, Hengstschläger M. Weichhart T. mTORC1 and mTORC2 as regulators of cell metabolism in immunity. FEBS Lett. 2017;591(19):3089-3103.

61. Kim LC, Cook RS, Chen J. mTORC1 and mTORC2 in cancer and the tumor microenvironment. Oncogene. 2017;36(16):2191-2201.

62. Tran Q, Lee H, Park J, Kim SH, Park J. Targeting Cancer metabolism - revisiting the Warburg effects. Toxicol Res. 2016;32(3):177-193.

63. Massari F, Ciccarese C, Santoni M, et al. Metabolic phenotype of bladder cancer. Cancer Treat Rev. 2016;45:46-57.
63. Wu S-H, Bi J-F, Cloughesy T, Cavenee WK, Mischel PS. Emerging function of mTORC2 as a core regulator in glioblastoma: metabolic reprogramming and drug resistance. Cancer Biol Med. 2014;11(4):255-263.

64. Wolf A, Agnihotri S, Munoz D, Guha A. Developmental profile and regulation of the glycolytic enzyme hexokinase 2 in normal brain and glioblastoma multiforme. Neurobiol Dis. 2011;44(1):84-91.

65. Mehta MM, Weinberg SE, Steinert EM, et al. Hexokinase 2 is dispensable for T cell-dependent immunity. Cancer Metab. 2018;6(1):10.

66. Katagiri M, Karasawa H, Takagi K, et al. Hexokinase 2 in colorectal cancer: a potent prognostic factor associated with glycolysis, proliferation and migration. Histol Histopathol. 2017;32(4):351-360.

67. Pinweha P, Rattanapornsompong K, CharoenSawan V, Jitrapakdee S. MicroRNAs and oncogenic transcriptional regulatory networks controlling metabolic reprogramming in cancers. Comput Struct Biotechnol J. 2016;14:223-233.

68. Chen B, Li H, Zeng X, et al. Roles of microRNA on cancer cell metabolism. J Transl Med. 2012;10:228.

69. Liu S, Chen Q, Wang Y. MiR-125b-5p suppresses the bladder cancer progression via targeting HK2 and suppressing PI3K/AKT pathway. Hum Cell. 2020;33(1):185-194. Jan.

70. Carter JV, O’Brien SJ, Burton JF, et al. The microRNA-200 family acts as an oncogene in colorectal cancer by inhibiting the tumor suppressor RASSF2. Oncol Lett. 2019;18(4):3994-4007.

71. Wu C-L, Ho J-Y, Chou S-C, Yu D-S. MiR-429 reverses epithelial-mesenchymal transition by restoring E-cadherin expression in bladder cancer. Oncotarget. 2016;7(18):26593-26603.

72. Wu C-L, Ho J-Y, Hung S-H, Yu D-S. miR-429 expression in bladder cancer and its correlation with tumor behavior and clinical outcome. Kaohsiung J Med Sci. 2018;34(6):335-340.

SUPPORTING INFORMATION
Additional supporting information may be found in the online version of the article at the publisher’s website.

How to cite this article: Chan T-C, Chen Y-T, Tan KT, et al. Biological significance of MYC and CEBPD coamplification in urothelial carcinoma: Multilayered genomic, transcriptional, and posttranscriptional positive feedback loops enhance oncogenic glycolysis. Clin Transl Med. 2021;11:e674. https://doi.org/10.1002/ctm2.674